Stockwinners Market Radar for May 07, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:48 EDT B2Gold discloses 10 positive COVID-19 cases at Fekola mine site - B2Gold announces that it has identified 10 positive COVID-19 cases at the Fekola mine site, 9 of which are currently asymptomatic, through the company's ongoing proactive COVID-19 testing and response plan. Fekola has implemented testing programs at the mine site, the exploration camp and in Bamako which are designed to identify asymptomatic carriers of COVID-19 and protect Fekola's employees, both site and Bamako-based, local community populations, and the general Malian population. These results do not have a material impact on operations and the mine continues to operate and maintain both quarterly and annual production budget guidance.

19:37 EDT J.C. Penney, Sephora affirm partnership - J. C. Penney and Sephora USA, Inc. announced they have reaffirmed their long-standing partnership to operate Sephora inside JCPenney. Both companies worked to resolve outstanding legal matters and have agreed to mutually beneficial revisions to their joint enterprise operating agreement.

19:07 EDT Appian withdraws FY20 guidance - Given the uncertainty regarding the duration of COVID-19 and its impact on the global economy, there is a broad range of possible results for this year. Therefore, Appian is withdrawing the full year 2020 guidance it provided on February 20, 2020 for cloud subscription revenue, total revenue, adjusted EBITDA, and non-GAAP net loss per share.

18:59 EDT JPMorgan sees Q2 NII roughly $14B - JPMorgan said in a regulatory filing that it expects Q2 NII, on a managed basis, to be roughly $14B, market dependent. The company added that it expects additions to the allowance for credit losses in Q2. Depending on the extent of the deterioration in macroeconomic conditions, the additions to the firm's allowance for credit losses could be meaningfully higher in aggregate over the next several quarters versus the additions in Q1 of 2020.

18:44 EDT Etsy CEO: Over 12M masks were sold in April - In an interview on CNBC's Mad Money, Josh Silverman said the company is all about supporting its sellers. Over 12M or $133M worth of face masks were sold in April, according to Silverman. The number of new shops doubled in April. Sellers are "rising to the occasion" and can respond to the changing needs of customers, he said.

18:13 EDT Macy's delays Q1 results to July 1 - Macy's announced a schedule for the release of its first quarter results. Due to the significant business disruption caused by the COVID-19 pandemic, and the subsequent impact on the financial statement preparation and reporting process, the company will release its first quarter earnings results and hold a related call on July 1. To further ensure the timely release of financial information, the company is planning to provide two updates to the investment community prior to the release of its results in July. On May 21, the company will release preliminary first quarter sales results pre-market. Later that day, Jeff Gennette, chairman and CEO and Paula Price, CFO, will participate in a fireside chat with Matt Boss, managing director, senior research analyst at J.P. Morgan. On June 9, the company will release select and preliminary first quarter financial results pre-market. Later that day, Gennette will participate in Cowen and company's 'The New Retail Ecosystem' virtual conference hosted by managing director and senior equity research analyst, Oliver Chen. The updates will be accessible to the media and general public via webcast.

17:56 EDT Boeing awarded $128.48M Missile Defense Agency contract modification - Boeing was awarded a $128.48M contract modification to a previously awarded on the Ground-based Midcourse Defense development and sustainment contract. The value of this contract, including options, is increased from $11.21B to $11.34B. The definitized scope of work requires continued support to Ground-based Midcourse Defense by manufacturing C2 boost vehicles, booster spare parts and associated avionics to maintain fleet and flight test programs. The period of performance is from January 31, 2018, to September, 30, 2022. This acquisition was executed on a sole-source basis. FY17 and FY18 research, development, test and evaluation funds in the amount of $52.89M have been obligated. To definitize the contract action, FY19 and FY20 research, development, test and evaluation funds in the amount of $65.07M were obligated at the time of award. The Missile Defense Agency is the contracting activity.

17:49 EDT Ovintiv reports Q1 net earnings $421M vs. ($245M) a year ago - Reports Q1 revenue $, consensus $1.66B.production averaged 215,200 BOE/d. Total Costs of $12.17 per BOE were below expectations. Q1 capital investments were $790M, below budget and consistent with previous expectations for a front-end weighted investment profile. Doug Suttles, CEO, stated, "These are challenging times, but we are using the flexibility we purposely built into our business to maintain financial strength and set our company up to thrive in whatever new environment emerges in the coming months and years. Our focus on cost reductions is making a huge difference today and for the future. We are confident we can deliver both $200M in cash cost reductions and a 20% improvement in capital efficiencies. Most of these savings will carry into 2021."

17:42 EDT Roku down over 10% at $123 per share after Q1 results

17:42 EDT Nielsen files Form 10 for proposed spin-off of Global Connect business - Nielsen announced the filing of an initial Form 10 Registration Statement with the U.S. SEC in connection with the company's proposed separation of the Nielsen Global Connect business into an independent, publicly traded company. The filing represents a significant milestone in the process of completing the separation, which the company anticipates effecting in the first quarter of 2021, subject to certain conditions.

17:38 EDT Trxade Group withdraws FDA EUA authorization for COVID-19 testing kit - Trxade Group announced that its wholly-owned subsidiary, Integra Pharma Solutions, has formally withdrawn its Emergency Use Authorization, or EUA, application in connection with its partner's manufacture of the SARS-CoV-2 IgM/IgG Antibody Rapid Test Kit from consideration in response to FDA guidance. The decision to withdraw the EUA application was made after much discussion with its partnered manufacturer. Per FDA guidance, only one EUA application is allowed per manufactured kit product. The EUA process is typically filed by manufacturers and there are specific guidelines that must be adhered to by the manufacturer, one of which includes reporting on test performance. Although Integra Pharma Solutions initially filed the EUA itself in collaboration with the manufacturer, in order to expedite the review and approval process, the parties now believe it makes more sense for the manufacturer to submit its own EUA application directly and for Integra Pharma Solutions to withdraw its previously filed EUA application. In its ongoing effort to combat this pandemic, Integra Pharma Solutions has secured additional manufacturer relationships for test kit products for distribution, thus ensuring adequate distribution channels to continue supplying healthcare facilities and authorized providers with test kits. All products carried by Integra Pharma Solutions are sourced from manufacturers that have submitted EUA applications for consideration.

17:36 EDT CryoLife initiates enrollment in PROACT Xa clinical trial - CryoLife announced that it has initiated enrollment in the PROACT Xa clinical trial, a prospective, randomized, trial to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin.

17:29 EDT TimkenSteel announces cost reductions actions - In response to the significant reduction in customer demand resulting from the COVID-19 crisis, the company has taken additional actions to further reduce operating expenses, conserve cash and maximize liquidity, such as: Reduced interim CEO and senior executives' base salaries by 20 percent and other executives' base salaries by 10 percent, effective May 1; Reduced cash retainer for its board of directors by 20 percent beginning with the second-quarter 2020, and reduced the value of the board's annual equity grant by 20 percent; Suspended company's 401(k) plan matching contributions for salaried employees, effective June 1; Implemented unpaid rolling furloughs for approximately 80 percent of salaried employees, beginning in early April; Aggressively reduced production schedules at all plants to align operations with customer demand, resulting in the temporary layoff of manufacturing employees; Reduced planned 2020 capital expenditures to a maximum of $25 million, a $5 million reduction from previously stated guidance; and Deferred Social Security payroll tax remittance as permitted by the CARES Act.

17:24 EDT Green Dot names Daniel Eckert chief product, strategy, and development officer - Green Dot announced that Daniel Eckert has joined the company as Executive Vice President & Chief Product, Strategy and Development Officer, leading all of Green Dot's product and Banking-as-a-Service (BaaS) platform business efforts. In this role, he will be responsible for product vision, strategy, design and development, from conceptualization through launch and post-launch, and on business development activities to acquire and grow major BaaS platform partnerships. "Daniel has been a valued Green Dot partner since he joined Walmart in 2010 and has a deep understanding of our business and the role we play in the financial lives of our customers," said Dan Henry, President and Chief Executive Officer. "While at Walmart, Daniel served as a catalyst for Green Dot's creativity, always pushing for continued innovation on the programs and platforms we support for this important relationship. He possesses a unique ability to balance customer value and satisfaction with a sustainable business model, and we're excited that he's joining our team to continue driving our growth."

17:15 EDT Uber says higher percentage of Rides customers are using Eats - Says realignments will bring reduction of $1B in fixed costs. Says Eats demand is enormous. Says COVID-19 had dramatic impact on Rides. Says global rides bookings down 80% in April. Says Eats performed extremely well. Says will look to partner with transit in the near future. Comments taken from Q1 earnings conference call.

17:12 EDT Monster Beverage provides update on impact from COVID-19 pandemic - The company said, "From the beginning of the COVID-19 pandemic, the Company's top priority has been the health, safety and well-being of its employees. Early in March 2020, the Company implemented global travel restrictions and work-from-home policies for employees who are able to work remotely. For those employees who are unable to work remotely, safety precautions have been instituted, which were developed and adopted in line with guidance from public health authorities and professional consultants. The Company is incredibly proud of the teamwork exhibited by its employees, co-packers and bottlers/distributors around the world who are ensuring the integrity of its supply chain. The Company's flavor manufacturing facilities, its co-packers, warehouses and shipment facilities, are all operating. Certain of the Company's bottlers/distributors have implemented modifications to their call points and service levels, but generally the Company's products remain available to consumers. In limited countries, which are smaller markets for the Company, the operations of its bottlers/distributors have been more affected. The impact of the COVID-19 pandemic on the Company's net and gross sales for the 2020 first quarter was not material. The Company's April sales were materially adversely impacted by the COVID-19 pandemic, however bottler/distributor sales of the Company's products to retail in the United States were markedly less adversely impacted. Since mid-March 2020, the Company has seen a shift in consumer channel preferences and package configurations, including an increase in at-home consumption and a decrease in immediate consumption. To date, the Company's sales in the second quarter have been adversely affected as a result of a decrease in foot traffic in the convenience and gas channel (which is the Company's largest channel) and food service on-premise, while the Company's e-commerce, club store, mass merchandiser, and grocery and related business remain stable. Currently, the Company does not foresee a material impact on the ability of its co-packers to manufacture and its bottlers/distributors to distribute its products as a result of the COVID-19 pandemic. In addition, the Company is not experiencing raw material or finished product shortages in its supply chain. As of March 31, 2020, the Company had $701.8 million in cash and cash equivalents, $233.5 million in short-term investments and $13.9 million in long-term investments. Based on currently available information, the Company does not expect the COVID-19 pandemic to have a material impact on its liquidity."

17:07 EDT Standex sees $1.5M in restructuring charges in Q4 - The company said, "Due to the economic impact of COVID-19 we have initiated expense reductions which will result in approximately $4 million in savings and $1.5 million in restructuring charges in fiscal fourth quarter 2020. In addition, we have reduced fiscal 2020 capital spending by approximately $10 million with the focus on maintenance, safety and our highest priority growth initiatives. Our strong balance sheet positions us well to invest selectively in our ongoing pipeline of organic and inorganic opportunities. We have approximately $220 million in available liquidity with net debt to adjusted EBITDA of under 1x. In addition, we generated free cash flow of $7.3 million in the third quarter with working capital turns improving ten basis points year-over-year to 4.7x. We also took actions to reduce our effective interest rate by 50 basis points or approximately $1 million annually."

17:06 EDT Standex sees sequential revenue decline in Q4 - In the fiscal fourth quarter, the company expects that each of its segments will experience some sequential revenue decline as a result of the COVID-19 pandemic. Electronics, Engraving, and Engineering Technologies segments are expected to have slight to moderate sequential revenue declines in the fourth quarter. The Food Service segment is likely to have the most significant sequential decrease in revenue as restaurants around the United States remain closed or focused solely on take out sales. In addition, the Scientific business will be impacted by the current market shift toward consumable protective equipment due to COVID-19 with less near-term emphasis on capital equipment expenditures.

17:03 EDT Universal Technical provides update on fiscal year outlook - Over 11,000 students are currently enrolled at UTI with approximately 8,300 students continuing to progress through the online curriculum. Approximately 500 students started in April 2020. Of the remaining enrolled students, approximately 600 students are on LOA and have only their hands-on, in-person labs remaining to complete the program, and another approximately 2,500 students are also on LOA, most of whom currently have expected return dates in May or June. Full year FY20 enrollments are currently pacing modestly ahead of fiscal year 2019. In-person, on-campus modified format labs were re-initiated. UTI continues to advance plans to welcome students back to remaining campuses. In Q3, UTI expects to receive a total of approximately $33M in grant funds from the CARES Act: Higher Education Emergency Relief Fund. At least 50% of these funds will be used to grant emergency financial aid to students impacted by COVID-19.The company intends to use a portion of the HEERF funds to offset costs that have arisen as a result of the COVID-19 crisis. These could include costs associated with the initial development and delivery of UTI's online educational programs, as well as the transition back to on-campus, in-person lab instruction when authorities deem it safe to do so.

17:00 EDT Flex suspends dividend, sees Q2 sales down high-single to low-double digits - The company states: "As a result of the material impact from the COVID-19 pandemic on our workforce and operations, as well as the lack of visibility as to the duration and potential outcomes of the pandemic, the Company is electing to suspend quarterly guidance for the June quarter and is unable to provide detailed fiscal year 2021 guidance at this time. However, the Company expects June quarter sales to decline by a high-single to low-double digits percentage sequentially, due to the ongoing impact of COVID-19."

16:56 EDT Farmland Partners: Direct impact of COVID-19 pandemic 'limited' so far - The company said, "So far, the direct impact of the COVID-19 pandemic on the company's business and operations has been limited. As broader sectors of the U.S. agricultural economy are affected through supply chain and commodity price disruptions, the company believes it may experience some yet largely unidentified impact in the medium term. In the long term, the company does not expect that the pandemic will affect materially the global demand for food, feed, fuel and fiber, and therefore the value of its farmland portfolio."

16:50 EDT Yelp reports Q1 app unique devices down 1% at 35M - Reports Q1 cumulative reviews up 14% at 211M. Reports Q1 adj. EBITDA $17M vs. $39M last year.

16:49 EDT Teradata names Steve McMillan CEO - Teradata announced that its Board of Directors has appointed Steve McMillan President and Chief Executive Officer, and a member of the Board of Directors, effective June 8, 2020. Mr. McMillan was previously at F5 Networks, Inc. as Executive Vice President of Global Services. He succeeds interim President and Chief Executive Officer, Victor Lund. Mr. Lund will step down from the Company's Board of Directors, effective upon the appointment of Mr. McMillan as CEO on June 8, 2020.

16:43 EDT Camden Property withdraws 2020 earnings guidance - Camden Property Trust said: "Given the uncertainty surrounding the social and economic impact from COVID-19, Camden has withdrawn its 2020 earnings guidance and will not be providing an update to its financial outlook at this time."

16:42 EDT Stamps.com drops 7% to $181.06 after USPS ends customized postage program

16:40 EDT Turtle Beach CEO says 'strong demand' for products in Q1 - "During the first quarter, as consumers around the world stayed home to help contain COVID-19, we saw strong demand for our products including record-setting retail sales and significant market share gains in March, which drove results that exceeded our expectations across all key financial metrics," said Juergen Stark, CEO, Turtle Beach. "Our headsets are also well-suited for learning and working remotely via video or audio conferencing, which we believe further increased demand. While we expect the increased demand for headsets may subside once stay-at-home measures are relaxed, we believe our sales for the year will exceed our prior forecast. According to NPD, U.S. retail sales of console headsets in the month of March for both the industry and for Turtle Beach were the highest ever, including in March of 2018, which was the start of the battle royale surge. The 39% increase in market sales for March partially offset the expected declines in January and February, resulting in total console gaming headset sales in the first quarter declining only 4% year-over-year. In addition to the industry's March surge in U.S. console headset sales, we gained over 500 basis points in revenue share in March, resulting in 57% growth in the U.S. retail sales of our headsets compared to March of 2019. We believe these results continue to be a testament to our strong brand, excellent products and our execution at retail. This is especially true in times like these, where retail, supply chain and operational execution can make a big difference both to us and to our retail partners. While it is not clear at this point how long this increased demand will continue, we now expect full year revenues, adjusted EBITDA and net income per diluted share to exceed our earlier forecasts. We recognize that these are unprecedented times and that consumer demand and retail supply logistics could fluctuate depending on the course of the pandemic and the response by governments and consumers."

16:39 EDT Stamps.com says USPS eliminating customized postage program on June 16 - Stamps.com said, "We received notification from the USPS that it was eliminating its customized postage program and also revoking our authorization to offer products pursuant to that program effective June 16, 2020. Our primary product subject to termination is offered by the Company under the brand PhotoStamps. The revenue and cost of revenue associated with these products appear on our financial statements as 'Customized postage.' While the Company continues discussions with the USPS to reverse or modify this decision, the financial impact associated with the elimination of this product is reflected in our updated financial guidance."

16:36 EDT Roku says impact of COVID-19 to remain for some time - The company says: "While we hope for a speedy end to the COVID-19 pandemic, it is likely that its effects will be with us for some time. Much uncertainty remains, but a few things are increasingly clear to us: streaming, and the ease and value it provides, is more relevant to consumers than ever; overall advertising expenditure in the U.S. is likely to fall in 2020, but we expect our ad revenues to still grow substantially year-over-year; Roku is well positioned to be an increasingly valuable partner as brands decide how to invest marketing resources most effectively; and, our outstanding talent is keeping our company highly productive. Although the Streaming Decade began differently than anyone could have imagined, we are confident the fundamental shift to streaming will continue, perhaps even faster than previously expected."

16:35 EDT Arena Pharmaceuticals lowers FY20 cash burn view to $400M-$430M

16:35 EDT PDC Energy sees 2020 production down approximately 10% vs. 2019 - PDC projects to generate more than $125 million of free cash flow, assuming $15 per Bbl WTI in the second quarter, $25 per Bbl WTI oil in the second half of 2020 and $2 per MMbtu NYMEX natural gas with NGL realizations of approximately $5 per barrel for the remainder of the year. Additionally, the Company projects second quarter oil realizations to be less than 35 percent of NYMEX, with a modest recovery in the third quarter and fourth quarter realizations slightly less than that of the first quarter. The Company anticipates investing approximately $100 million in the Delaware basin, down from an original estimate of $300 million provided in February. The 2020 Delaware basin capital program was recently completed for the year, with the expectation to spend less than $20 million on various leasing, non-operations projects and facility investments the remainder of the year. Production for 2020 is expected to decrease approximately ten percent from 2019 pro forma levels to a range of 170,000 to 180,000 Boe per day, with anticipated oil production of 60,000 to 65,000 Bbls per day. The Company currently expects to curtail between 20 and 30 percent of its volumes in May, with additional curtailments likely in June. Based on current price, activity and curtailment assumptions, the Company expects second and third quarter volumes toward the bottom of its full-year range prior to an expected increase in the fourth quarter.

16:31 EDT Arrowhead discloses COVID-19 development program - As part of its Q2 announcement, Arrowhead disclosed that it has :"started a development program to address the current novel coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens. No additional details about this program are being disclosed at this time."

16:29 EDT News Corp expects more significant COVID-19 impact in fiscal Q4 - News Corp said, "The impact of the COVID-19 pandemic and measures to prevent its spread have created significant volatility, uncertainty and economic disruption and are affecting the Company's businesses in a number of ways, as detailed in the Company's Current Report on Form 8-K filed on April 13, 2020. While these effects were not material to the Company's results of operations for the three and nine months ended March 31, 2020, as they began to materialize toward the end of the quarter, the Company expects a more significant impact in the fourth quarter of fiscal 2020, particularly as containment measures in a number of its operating geographies have been extended into May or beyond."

16:26 EDT SailPoint withdraws previously issued guidance for FY20 - "While we were pleased with our Q1 results and have experienced a strong start to the second quarter, the duration and economic impact of COVID-19 is still unknown and can potentially lead to a wide range of outcomes for us," said Jason Ream, CFO. "Given the high level of macro uncertainty, we are not providing guidance for the second quarter and withdrawing our previously issued guidance for the full year. We will reassess this position after the second quarter."

16:25 EDT Hanger does not see sufficient liquidity throughout remainder of 2020 - Hanger said: "Beginning in the last weeks of March 2020, the Company's business volumes began to be adversely affected by the COVID-19 pandemic. As federal, state and local authorities implemented social distancing and suppression measures to respond to an increasing number of nationwide COVID-19 infections, the Company experienced a decrease in patient appointments at its patient care clinics and in its general business volumes in both of its segments. These adverse volume effects further expanded during April. During the month of April 2020, patient appointment volumes in our Patient Care clinics decreased by approximately 40 percent as compared with the same period in 2019. As of the end of April 2020, we had temporarily closed 27 patient care clinics and another 179 clinics were open for reduced hours or by appointment only. Billings for componentry delivered to independent providers of orthotics and prosthetics by the Company's distribution services business decreased by approximately 40 percent as well during the month of April 2020. Due to significant geographic, product mix and timing differences, there can be no assurance that these volumes or billing amounts will be reflective of the Company's results for the second quarter as a whole, and are solely provided for the purposes of giving context to the magnitude of the effect of the COVID-19 pandemic on the Company's business during April 2020...While the Company cannot forecast with certainty the ultimate extent of the impacts from or the duration of the COVID-19 pandemic, or the degree to which the cost mitigation and liquidity management strategies it has implemented will offset declines in its cash flows caused by the COVID-19 pandemic, it does currently believe that these measures, when accompanied if necessary by additional funding sources, if available, and further cost reduction actions, will enable it to maintain sufficient liquidity throughout the remainder of 2020 and subsequent periods."

16:24 EDT Power Integrations raises quarterly dividend to 21c from 19c per share - The dividend will be paid on June 30, 2020 to stockholders of record as of May 29, 2020.

16:20 EDT Trade Desk withdraws FY20 guidance - The company states: "As a result of the impact of the Covid-19 pandemic on economic activity and advertiser demand, The Trade Desk is not providing financial guidance for revenue or Adjusted EBITDA for the second quarter of 2020. In addition, the Company is withdrawing its outlook for gross spend, revenue and Adjusted EBITDA for the full year 2020."

16:19 EDT Avid Technology puts plan into place to reduce operating expenses - Avid has put in place a plan to reduce its operating expenses, non-material cost of goods sold, and capital expenditures to offset its expectations for the decline in revenues for products and professional services due to the impact of the COVID-19 global pandemic. The Company has implemented actions that are expected to reduce Non-GAAP Operating Expenses by at least $30 million year-over-year in 2020 from a combination of temporary furloughs and wage reductions for all staff, through the end of the third quarter, with senior management and the board of directors taking commensurate reductions; a hiring freeze; elimination of merit increases and 401K match; reduced marketing spending due to the cancellation of trade shows; reduction in usage of consultants, contractors and outside services, and reduction in other business activities, including travel and other discretionary spending. The cost savings actions are also expected to reduce non-material cost of goods sold by at least $10 million year-over-year in 2020, which is expected to protect gross margin at the expected lower product and professional services volumes.

16:18 EDT Motorola Solutions has taken actions to reduce expenses - The company said, "In response to the evolving COVID-19 pandemic, the company has implemented preparedness plans to keep its employees and customers healthy and safe, as well as to ensure continued operations and business continuity. Safety measures during this outbreak include having office workers work remotely, suspending employee travel, withdrawing from certain industry events, increased cleaning, encouraging face coverings and using thermal scanning. The company has ensured customer continuity by fulfilling several emergency orders, completing remote software maintenance where possible, and the visitation by field workers to customer sites to keep mission-critical networks operating. Supply chain partners have been supportive and continue to do their part to ensure that service levels to the company and its customers remain solid. Additionally, the pandemic has impacted the company's professional commercial radio business and delayed engagement and deployments with some of its state and local customers in the near term which may impact future revenue. The company has also taken actions in a number of areas to reduce our operating expenses. "

16:14 EDT Dicerna names Douglas Pagan as new CFO - Dicerna Pharmaceuticals announced that Douglas Pagan will become Dicerna's chief financial officer and a member of the Company's executive leadership team, effective May 26, 2020. Dicerna previously announced the retirement of its current CFO, Jack Green, who will continue with the Company in a consulting capacity to ensure a successful transition.

16:14 EDT Uber reports Monthly Active Platform Consumers 103M vs. 93M last year

16:12 EDT SunPower expects to complete planned company split at end of Q2 - "We had a strong start to the year, exceeding our margin and adjusted EBITDA guidance driven by strong global DG demand and outperformance by our U.S. channels business," said Tom Werner, SunPower CEO and chairman of the board. "However, we have seen a material impact across the industry and our business, caused by the COVID-19 virus pandemic during the second quarter. Our primary focus during this disruption remains on the safety and well-being of our employees, working closely with our partners and maintaining our industry leading customer service levels. Despite the disruption, our fundamentals remain strong and we believe that our differentiated business model, rigorous prioritization of cost containment and continued investment will position the company well post-pandemic." "Looking forward, we remain very confident in the significant longer term growth opportunity in solar and our investment priorities are consistent with this potential. These investments include our next generation Maxeon technology, Equinox and Helix storage solutions and our digital initiatives. We have also instituted a number of programs that we expect to result in cost and cash savings of up to $100 million in 2020. Finally, we expect to complete our planned company split into two, independently focused, pure-play solar companies by the end of the second quarter pending closing conditions. With further investment in our industry-leading technology and initiatives in place to strengthen our balance sheet, we remain focused on emerging from the current disruption in a much stronger competitive position."

16:10 EDT Cutera notes withdrawn FY20 guidance - As previously announced on April 3, 2020, Cutera has withdrawn its previously announced full-year 2020 guidance due to uncertainty over the magnitude and duration of the impacts from the COVID-19 pandemic on its financial results.

16:09 EDT Live Nation targeting $600M cost reduction program in 2020 - Targeting $1B cash management program in 2020.

16:07 EDT Booking Holdings reports impairments for OpenTable and KAYAK goodwill - Net loss in the first quarter of 2020 includes impairments of $489M for OpenTable and KAYAK goodwill and $100M for an investment in equity securities, Booking Holdings said.

16:03 EDT Allscripts withdraws prior financial outlook for FY20 - Given the current uncertainty presented by the COVID-19 pandemic, Allscripts is withdrawing its prior financial outlook for the full-year 2020.

16:02 EDT Fiserv names Frank Bisignano next CEO - Fiserv announced that its Board of Directors has unanimously elected Frank Bisignano to succeed Jeffery Yabuki as Chief Executive Officer as of July 1. Yabuki will step down following a distinguished 15-year career with the company. To ensure a seamless transition, Yabuki, Chairman of the Fiserv Board, will continue to serve as Executive Chairman for the remainder of 2020. "With the successful integration of First Data well underway, this is the right time for Frank to lead the next phase of the company's evolution," said Yabuki. "Frank and I have had the pleasure of working closely over the past 18 months - and I am highly confident he brings the skill and experience to deliver the leadership that is needed today, while building for tomorrow. In addition to spearheading our integration efforts and significant COVID-19 response, Frank has been leading our global businesses with an absolute commitment to excellence. While Frank will bring new ideas and perspectives as CEO, he fully embraces the strategic and capital foundation of the Fiserv value creation playbook. I look forward to continuing to partner with Frank through the end of the year, and know he will continue to deliver superior results for the benefit of our stakeholders."

15:41 EDT Box CEO talks about deeper integration with Zoom Video - Box (BOX) CEO Aaron Levie says today's announcement of new features represents an acceleration of planned updates that had been intended throughout the year as the company responds to the new "work from home" trend. Levie is being interviewed on CNBC.

15:18 EDT Salient Midstream trading halted, news pending

14:54 EDT Chesapeake Utilities raises quarterly dividend 8.6% to 44c per share - The board of directors of Chesapeake Utilities Corporation voted to increase the quarterly cash dividend on the company's common stock from 40.5c per share to 44c per share. The board's action raises the 2020 annualized dividend 14c per share from $1.62 to $1.76 per share, which represents an 8.6% increase. The 44c per share dividend will be payable July 6, 2020 to all shareholders of record at the close of business on June 15, 2020.

14:48 EDT Chesapeake raises quarterly dividend 8.6% to 44c per share - The board of directors of Chesapeake Utilities Corporation voted to increase the quarterly cash dividend on the company's common stock from 40.5c per share to 44c per share. The board's action raises the 2020 annualized dividend 14c per share from $1.62 to $1.76 per share, which represents an 8.6% increase. The 44c per share dividend will be payable July 6, 2020 to all shareholders of record at the close of business on June 15, 2020.

14:14 EDT Bungie's 'Destiny 2' coming to next-gen consoles - Bungie said via Twitter that its online shooter video game "Destiny 2," which previously was published by Activision (ATVI), will be on next-generation platforms, such as the Xbox Series X (MSFT). The game is currently available on PC, PlayStation 4 (SNE), Xbox One, and Google Stadia (GOOG). Reference Link

14:02 EDT NACCO Industries trading resumes

13:42 EDT Nacco Industries engaged in exploration of options for Coal Creek - Nacco Industries, together with its wholly owned subsidiary, The North American Coal Corporation, responded to Great River Energy's announcement concerning its Coal Creek Station power plant in Underwood, ND - the sole customer of The Falkirk Mining Company, a subsidiary of North American Coal. "Earlier today, Great River Energy, the owner of the Coal Creek Station, issued a press release announcing its intent to prematurely retire the Coal Creek Station power plant in the second half of 2022 and modify the Spiritwood Station power plant in Jamestown, ND to be fueled with natural gas. Great River Energy and The Falkirk Mining Company have been contract partners since 1974 under an agreement to provide fuel to the 1,151-megawatt Coal Creek Station power plant through 2045," Nacco said. J.C. Butler, President and CEO of NACCO and North American Coal, stated: "As Great River Energy is willing to consider opportunities to sell Coal Creek Station, we are actively engaged in the exploration of options to allow for the transfer of the plant to one or more third parties, which would preserve jobs at both Coal Creek Station and the Falkirk Mine. The Falkirk Mining Company currently has 480 full-time employees and in 2019 delivered 7.4 million tons of lignite coal to Coal Creek Station, a modest number of which were then shipped to Spiritwood Station."

13:39 EDT iHeartMedia, LiveXLive Media extend live stream partnership - LiveXLive Media (LIVX) and iHeartMedia (IHRT) announced a multiyear extension through 2022 of the livestream partnership which includes more than 25 iHeartRadio festivals and theater shows annually and the addition of five new shows - the iHeartRadio Podcast Awards, the 98.7 ALT Summer Camp, the iHeartCountry Veteran's Day event and iHeartRadio's CES event. The extended agreement also includes LiveXLive's exclusive distribution on its platform of two more of iHeartMedia's top annual events - the iHeartRadio Music Festival and iHeartRadio Jingle Ball -- to international audiences. "Our partnership with iHeartMedia has shown the appetite audiences around the world have for watching their favorite artists from the comfort of home or on-the-go. We're thrilled to bring even more content to these audiences globally and to deliver the best experience for both fans and artists alike with iHeartMedia over the next few years and beyond" said Robert Ellin, LiveXLive's CEO and Chairman.

13:26 EDT NACCO Industries trading halted, news pending

12:47 EDT Pinterest launches Shopify partnership - Pinterest (PINS) said in a blog posting: "As more people than ever come to Pinterest to find inspiration for supporting small businesses, furnishing their work from home setups, gifts to cheer up friends, and activities to do with their kids, there's an increasing opportunity for retailers to get their products in front of Pinners. We're launching a new app with Shopify (SHOP) that gives their more than one million merchants a quick way to upload catalogs to Pinterest and turn their products into shoppable Product Pins, in just a few clicks.The Pinterest app on Shopify includes a suite of shopping features like tag installation, catalog ingestion, automatic daily updating of products, and an ads buying interface. For Shopify merchants, this means easy set up and access to distribution across Pinterest with or without ads, as well as reporting and results tracking to maximize reach. The app automatically creates a connection between the individual store and Pinterest, so the merchant doesn't need to edit code or add development resources, making it seamless for businesses of all sizes." Reference Link

12:35 EDT Google launches Read Along app for school age kids amid coronavirus - Google announced the launch of Read Along to help elementary school age children to practice reading and educational engaged amid the coronavirus. The company said in a blog posting: "With many students currently at home due to school closures, families around the globe are looking for ways to help children grow their reading skills. To support families, today we're sharing early access to Read Along by Google. It's an Android app for children 5+ years old that helps them learn to read by giving verbal and visual feedback as they read stories out loud...Read Along uses Google's speech recognition technology to help develop literacy skills, and first launched in India, where it is available as "Bolo") After receiving encouraging feedback from parents, we're excited to share this app with more young learners around the globe...Read Along helps kids independently learn and build their reading skills with the help of an in-app reading buddy named Diya. As kids read out loud, Diya uses Google's text-to-speech and speech recognition technology to detect if a student is struggling or successfully reading the passage. She gives them positive and reinforcing feedback along the way, just as a parent or teacher would. Children can also tap Diya at any time for help pronouncing a word or a sentence." Reference Link

12:08 EDT North American rail traffic dropped 21.1% in week ended May 2 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending May 2, as well as volumes for April 2020.U.S. railroads originated 980,535 carloads in April 2020, down 25.2%, or 329,693 carloads, from April 2019. U.S. railroads also originated 1,095,423 containers and trailers in April 2020, down 17.2%, or 227,165 units, from the same month last year. Combined U.S. carload and intermodal originations in April 2020 were 2,075,958, down 21.2%, or 556,858 carloads and intermodal units from April 2019. Total U.S. weekly rail traffic was 416,954 carloads and intermodal units, down 22.1% compared with the same week last year.Total carloads for the week ending May 2 were 189,190 carloads, down 29.6% compared with the same week in 2019, while U.S. weekly intermodal volume was 227,764 containers and trailers, down 14.5% compared to 2019.North American rail volume for the week ending May 2, 2020, on 12 reporting U.S., Canadian and Mexican railroads totaled 270,855 carloads, down 28.3% compared with the same week last year, and 309,731 intermodal units, down 13.4% compared with last year. Total combined weekly rail traffic in North America was 580,586 carloads and intermodal units, down 21.1%. North American rail volume for the first 18 weeks of 2020 was 11,401,713 carloads and intermodal units, down 9.9% compared with 2019. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Genesee & Wyoming (GWR), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link

12:00 EDT ServiceMaster falls -20.1% - ServiceMaster is down -20.1%, or -$6.47 to $25.75.

12:00 EDT Vista Outdoor falls -29.9% - Vista Outdoor is down -29.9%, or -$2.90 to $6.80.

12:00 EDT Twilio rises 36.6% - Twilio is up 36.6%, or $44.83 to $167.23.

11:59 EDT Flir Systems to provide temperature scanners for GM, CEO says - Flir Systems (FLIR) CEO Jim Cannon, during an interview on CNBC, discussed the impact of COVID-19 on his business, including the increased demand for thermal imaging and temperature scanning devices. General Motors (GM) is among the companies that will be using Flir temperature scanners, Cannon noted during his appearance on the business news network.

11:47 EDT Gilead announces approval of Veklury in Japan for severe COVID-19 - Gilead Sciences announced that the Japanese Ministry of Health, Labour and Welfare has granted regulatory approval of Veklury, remdesiver, as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19, under an exceptional approval pathway. The exceptional approval was granted due to the COVID-19 pandemic and references the Emergency Use Authorization of remdesivir in the United States. The approval is based on clinical data from the U.S. National Institute of Allergy and Infectious Diseases' global Phase 3 trial, Gilead's Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19, and available data from Gilead's compassionate use program, including patients in Japan.

11:17 EDT Wex reduced U.S. workforce by 2% due to COVID-19 uncertainty - Wex announced that in response to COVID-19 uncertainty, the company implemented actions to reduce discretionary capital and operating expenditures, adjust its cost structure and preserve its financial flexibility and liquidity position, including: Reducing compensation for board members and executive officers; Enforcing expense controls, including limiting non-essential expenditures; Re-scaling worldwide headcount to match current and anticipated business needs; and strategically evaluating its capital expenditure and investment priorities to focus resources on high-growth areas. The total savings resulting from these changes are expected to be approximately $60M-$65M compared to original guidance. The company believes WEX's balance sheet and liquidity position "remain strong." In a regulatory filing, Wex said it reduced its U.S. workforce by 2% and furloughed 3%.

11:13 EDT Wex says not required to close eNett deal on 'material adverse effect' - Wex said earlier in its earnings release, "The Company has analyzed the eNett and Optal situation closely with specialist advisors and has concluded that the pandemic and conditions arising in connection with it have had, and continue to have, a material adverse effect on the businesses. Because of this material adverse effect, WEX has advised eNett and Optal that it is not required to close the transaction pursuant to the terms of the purchase agreement."

10:43 EDT Manhattan Bridge Capital lowers dividend to 10c per share - Manhattan Bridge Capital announced that its board of directors has declared a quarterly dividend of 10c per share to be paid to all shareholders of record on July 10. The dividend will be paid on July 15. Assaf Ran, Chairman of the Board and CEO, stated, "As we deal with the dynamic consequences of the COVID-19 crisis, we feel that $0.10 is the appropriate dividend for the second quarter. At this point our problems seem manageable, but we are prepared in the event that conditions worsen."

10:34 EDT JetBlue: Too early to say if bookings trend is permanent

10:32 EDT JetBlue thinks demand bottomed out in April

10:30 EDT JetBlue still sees need to enter Transatlantic market

10:26 EDT JetBlue seeks to reduce daily cash burn further to $7B-$9B

10:16 EDT JetBlue plans to reduce many markets to less than 1 flight per day

10:08 EDT JetBlue: Demand environment 'exceptionally challenged' due to coronavirus - Comments taken from Q1 earnings conference call.

10:00 EDT Lannett falls -19.5% - Lannett is down -19.5%, or -$1.85 to $7.63.

10:00 EDT Fastly rises 24.8% - Fastly is up 24.8%, or $5.72 to $28.77.

10:00 EDT ION Geophysical rises 152.1% - ION Geophysical is up 152.1%, or $2.54 to $4.21.

09:47 EDT Twilio rises 26.3% - Twilio is up 26.3%, or $32.17 to $154.57.

09:47 EDT ION Geophysical rises 144.9% - ION Geophysical is up 144.9%, or $2.42 to $4.09.

09:40 EDT Vista Outdoor trading resumes

09:36 EDT Atossa Therapeutics announces interim Phase 2 data from endoxifen treatment - Atossa Therapeutics announced positive interim results from its Phase 2 study of oral Endoxifen to treat breast cancer in the window of opportunity between diagnosis of breast cancer and surgery. A statistically significant reduction of about 74% in tumor cell proliferation was achieved over the 22 days of dosing. Proliferation was measured by Ki-67, a recognized standard measurement of breast cancer cell proliferation. The purpose of this study is to determine if Atossa's oral Endoxifen reduces breast cancer tumor cell proliferation as measured by several biomarkers, including Ki-67. The open-label study was designed to permit an interim analysis of the Ki-67 change. The requirement was to achieve a meaningful Ki-67 change in at least two of eight patients. All patients (N=6) experienced a significant reduction in Ki-67. A summary of these results includes: Ki-67 was reduced by more than 50% in every patient in the window of opportunity between initial biopsy and surgery, with an overall reduction of 74%. All six patients had a Ki-67 below 25% after treatment. In a paper entitled, "Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients," Ki-67 was an independent prognostic value for predicting overall survival in ER+ breast cancer patients. Ki-67 levels below 25% were associated with the lowest risk of death in this systematic review and meta-analysis. Treatment ranged from 16-40 days with an average of 22 days. There were no safety or tolerability issues, including vasomotor symptoms such as hot flashes and night sweats, which are often a tolerability challenge for patients on tamoxifen. Results of the study are consistent with the results in a recent compassionate use, or expanded access, single-patient study with oral Endoxifen. At the end of 2018, the FDA approved a single patient IND for a breast cancer patient to receive our oral Endoxifen in the window of opportunity. That patient experienced a 50% reduction in Ki-67 after taking daily doses for 20 days prior to her surgery. Based on these results, an additional compassionate use approval was granted by the FDA for the same patient, who has continued to take oral Endoxifen for over a year in the adjuvant setting following her surgery. Based on these positive results, Atossa is continuing to enroll the remaining 19 patients in the study and will then seek regulatory approval to move into a Phase 3 study.

09:35 EDT AB InBev feels 'very good' about liquidity postion - Says in "very comfortable position." Will continue to prioritize debt repayment.

09:34 EDT Cerence trading halted, volatility trading pause

09:31 EDT Allied Motion trading halted, volatility trading pause

09:30 EDT Vislink to hold remote Annual Meeting on new date - Vislink Technologies announced that the Company plans to adjourn the Annual Meeting of Stockholders, scheduled to be held on Friday, May 8, 2020, to Friday, May 22, 2020 by means of remote communication, which will be provided by the Company in a separate communication ahead of the adjourned meeting. The Annual Meeting will continue to be held at 9:00 a.m. Due to the COVID-19 pandemic, we are holding the Annual Meeting by remote communications in order to support the health and well-being of our shareholders and Company personnel. Furthermore, delays in mailings and related fallout from the COVID-19 pandemic have resulted in some shareholders not receiving notices and requiring other means of transmission of proxy materials and providing additional means for shareholders to consider and vote their shares.

09:29 EDT Telos Corp awarded $66.4M U.S. Air Force contract - Telos Corporation announced that it has been awarded a $66.4M contract including option line items to deliver modules and kits with inclusive baseline cybersecurity posture for equipment being provided in support of the Theater Deployable Communications Black Core Architecture upgrade.

09:29 EDT Gritstone Oncology announces anticipated upcoming milestones - Present additional efficacy and safety data from the Phase 1 studies of SLATE and GRANITE in a company-hosted webcast event in mid-2020. Initiate Phase 2 expansion cohorts in the second half of 2020. Initiate Phase 2 adjuvant study/studies in early 2021. Nominate a lead bispecific antibody development candidate directed towards a novel solid tumor-specific HLA-peptide complex in the second half of 2020.

09:26 EDT Western Digital up 1.7% following Q1 earnings conference call

09:25 EDT SmileDirectClub expands services for dental community amid COVID-19 - SmileDirectClub announced the sale of its at-home impression kits to dentists and orthodontists to meet the demand from these doctors to help them safely and remotely provide oral care to their patients during the ongoing pandemic. The company announced last month it is also offering its telehealth platform free of charge to any dentist or orthodontist in the U.S. or Canada to communicate with their patients remotely. The prescription-only at-home impression kits may be used by providers to make mouth molds for retainers, night guards and to assess other dental needs, allowing the doctor to evaluate and address a patient's oral needs remotely, and avoid office visits while the pandemic continues. These kits will be sent to the doctors' patients directly pursuant to their prescription and instructions, and will have pre-paid return labels to the dentist or orthodontist office. This is another step in SmileDirectClub's entrance into the wholesale channel and ability to support the dental community's use of telehealth.

09:22 EDT Aldeyra up 4.1% after reporting Q1 results

09:21 EDT Rafael announces in vivo study of CPI-613 with Azacitidine, Venetoclax - Rafael Pharmaceuticals announced that it has entered into a research collaboration with a major medical institution and renowned researchers to evaluate the efficacy of CPI-613 in combination with chemotherapy agents azacitidine and venetoclax on acute myeloid leukemia models. Rafael also has a Phase 3 clinical trial in AML to evaluate the efficacy of devimistat in combination with chemotherapy agents cytarabine and mitoxantrone. The trial is currently enrolling patients in nearly 50 sites globally. Rafael's additional trials in hematological malignancies include a Phase 2 trial in Burkitt's lymphoma/leukemia, a Phase 1/2 trial in myelodysplastic syndrome, and a Phase 1 trial in T-cell lymphoma.

09:20 EDT ShiftPixy announces international expansion into Canada - ShiftPixy announced its first international expansion, ShiftPixy Canada, to meet the recent increased interest from multi-unit restaurant operators in Canada. The company is currently in the process of completing all the necessary registrations in each of Canada's ten provinces and plans to begin offering its end-to-end restaurant solution to Canadian customers as soon as that process is complete in the coming months. The company has established ShiftPixy Canada as a wholly-owned subsidiary. With its $90 billion foodservice industry, Canada represents ShiftPixy's first international expansion, a continuation of the company's aggressive growth strategy that has evolved from California-only followed by nationwide service across the US. The company will continue its expansion to international markets that meet its criteria and are ripe for disruption in the restaurant industry. As restaurants face an uncertain future globally, operators are seeking simple, digital solutions that can help them not only weather the storm but also better reinforce their business infrastructure. Furthermore, third-party delivery partners are eating into restaurants' already thin margins. ShiftPixy's human capital management, online ordering and native delivery services offer Canadian restaurants an all-in-one platform. In addition to Canada, ShiftPixy is working with relevant partners and regulators in nations throughout Latin America and Japan in order to meet the demand in those markets.

09:18 EDT Calumet Specialty Products lowers FY20 CapEx to $50M-$60M from $80M-$90M

09:18 EDT Tegna up 2.3% after reporting Q1 results

09:18 EDT ARCA Biopharma announces presentations of Gencaro clinical data - ARCA biopharma announced that clinical data evaluating Gencaro as a potential treatment for atrial fibrillation in patients with heart failure was presented at the 2020 Heart Rhythm Scientific Sessions, the annual scientific conference of the Heart Rhythm Society. While the in-person meeting was cancelled due to the continued global escalation of COVID-19, HRS has provided author presentations virtually through its online learning platform Heart Rhythm 365 and all abstracts will be published in a supplement to the May edition of the Heart Rhythm Journal. The data come from a Phase 2 clinical trial, GENETIC-AF, that enrolled 267 HF patients with a current or recent history of paroxysmal or persistent AF and the ADRB1 Arg389Arg genotype. Patients were randomized to bucindolol or the active comparator, metoprolol succinate, and were followed for approximately 24 weeks. "Pharmacogenomic Guided Beta-Blocker Therapy with Bucindolol Reduces Atrial Fibrillation Burden Compared to Metoprolol Succinate: The GENETIC-AF Trial," authored by Jonathon P. Piccini et al, presented data from the device substudy of the GENETIC-AF trial. A total of 69 HF patients underwent continuous heart rhythm monitoring via implanted cardiac devices to evaluate the total time spent in AF during 24 weeks of follow-up, also known as cumulative AF burden. The paper's authors concluded that: Bucindolol decreased cumulative AF burden by 26% compared to active control. Treatment effect estimates for cumulative AF burden were consistent with time to first AF event analyses. Cumulative AF burden evaluates more information than time to first event methods, providing greater power to detect clinically meaningful differences between groups with limited sample size. "Impact of Pharmacogenetic-guided Bucindolol versus Metoprolol Succinate on the Overall Burden of Clinical Events in Patients with AF and Heart Failure: The GENETIC-AF Trial," authored by Jeff S. Healey et al, presented data on the frequency of AF rhythm interventions and cardiovascular adverse events in the GENETIC-AF trial. The paper's authors found that: Bucindolol decreased a composite endpoint of AF interventions and CV adverse events by 30% compared to active control. Bucindolol decreased AF interventions by 33% compared to active control. Significant and numerically greater results were observed in a subgroup previously identified by precision therapeutic phenotyping. Similar significant results were observed for a subgroup of the PTP cohort with baseline LVEF values of 40% to 55%. "Bucindolol is Associated with a Lower Incidence of Dose Limiting Bradycardia in Heart Failure Patients with Atrial Fibrillation: The GENETIC-AF Trial," authored by William T. Abraham et al, reviewed drug dosing and safety data for the GENETIC-AF trial. The paper's authors found that: Bucindolol was associated with a 55% lower incidence of bradycardia compared to active control. Bradycardia was associated with a 4-fold increase in study drug dose reductions. Differences in study drug dosing were primarily observed in patients with heart rates less than 60 beats per minute, which was much more common in the metoprolol group. Fewer bradycardia adverse events in the bucindolol vs. metoprolol groups. Bradycardia may limit dosing of conventional beta-blockers in HF patients with AF, which would be expected to compromise effectiveness for reducing HF clinical events. The individual presentations can be found on the Scientific Publications page of the ARCA website and at HRS' Heart Rhythm 365.

09:14 EDT Uber leading $170M investment round in Lime - Lime announced that Uber (UBER) is leading a $170M investment round with participation from Alphabet (GOOGL), Bain Capital Ventures, GV and other existing and new investors. "This investment reaffirms Lime's market strength and positions the company to build a long-lasting business that empowers people with sustainable, safe and affordable transportation options," the scooter company said. As part of the investment, Lime has acquired JUMP's business operations and will further expand its mobile app integration with Uber. "Today's announcement means that riders around the world will have even more integrated micromobility options at their fingertips, making car-free travel easier than ever before. In almost all markets where Lime and Uber operate, users will be able to turn to both the Lime and Uber app to unlock world-class products and services," the company added. Reference Link

09:12 EDT 8i Enterprises Acquisition Corp. announces amendment to Diginex agreement - 8i Enterprises Acquisition announced that it has amended the Share Exchange Agreement with Diginex Limited, a blockchain financial services and technology company, to extend the date by which it much complete its business combination to June 23, 2020 and to include new covenants and closing conditions of the parties. JFK has called a special shareholder meeting for June 15, 2020 to vote on the business combination along with the other proposals. All parties remain committed to the business combination, which if consummated, will result in Diginex becoming the first company listed on Nasdaq with a digital asset exchange. The Amendment, among other things, increases (i) the number of shares issuable to the Diginex shareholders at the closing of the business combination from 20,000,000 to 25,000,000, (ii) the number of earnout shares the Diginex shareholders would be entitled to receive upon the attainment of certain stock price targets from an aggregate of 5,000,000 over the three-year period after the closing of the business combination to 12,000,000 over the four-year period after the closing of the business combination, and (iii) from 4,200,000 to 5,600,000 the number of options to purchase ordinary shares of the combined company that will be issued in exchange for the currently outstanding options to purchase ordinary shares of Diginex. The parties have also agreed, among other things, that Diginex will use commercially reasonable efforts to raise gross proceeds of $15,000,000 of additional capital through a private placement prior to the closing of the business combination and that it will be a closing condition that JFK will have at least $15,000,000 in its trust account after taking into account redemptions by JFK's shareholders, but prior to taking into account JFK's liabilities for any fee and costs related to the business combination. Diginex continues to execute on its product roadmap, with the ongoing roll-out of various products including Helios, a warm custody solution for digital assets, in which further supports the company's execution capability. Diginex's institutionally focused digital asset exchange is anticipated to be available to the public in May 2020.

09:11 EDT Spirit in talks with Airbus to defer some 2020, 2021 aircraft deliveries

09:10 EDT Aleafia Health's Emblem Germany submits EU-GMP application - Aleafia Health's indirect subsidiary, Emblem Germany GmbH, has formally submitted its application to German regulators for EU Good Manufacturing Practices certification. The Company's newly licensed Paris Facility has been purpose built to meet EU-GMP certification requirements, pharmaceutical-grade production's highest standard, and as a result, provides wide access to global markets. The application, if successful, would allow the Company's Paris Facility to produce and export EU-GMP certified cannabis products to the European Union. Cannabis production operations commenced on May 6, 2020 at the Paris Facility Phase II expansion, only three business days following receipt of the amended Health Canada licence. Aleafia Health indirectly owns 60 percent of Emblem Germany, by way of a joint-venture between Emblem and German pharmaceutical wholesaler and logistics company, Acnos Pharma. It is difficult to ascertain the timeline for securing certification, but the Company intends to continue preparing for an eventual facility inspection. Aleafia Health and Acnos' senior management are directing the effort and have previously led the build-out, certification and operation of multiple EU-GMP certified pharmaceutical production facilities in The Netherlands, Germany and North America. Later this month, Acnos is expected to complete a new state-of-the-art pharmaceutical production and supply chain facility in Aachen Brand, Germany. It contains a dedicated cannabis distribution hub that Acnos owns and Emblem Germany will operate, allowing the Company to commence sales upon receipt of necessary German export and import permits.

09:09 EDT Eton Pharmaceuticals confirms first-to-file patent challenge on Elcys - Eton Pharmaceuticals disclosed that it has been confirmed as the first filer of an Abbreviated New Drug Application against Exela Pharma Science's Elcys. Eton's Paragraph IV certifications challenge the validity of U.S. Patent Nos. 10,478,453 and 10,583,155, which were issued to Exela Pharma Sciences in 2019 and 2020, respectively. Eton is the first company to have filed a substantially complete abbreviated new drug application containing a Paragraph IV certification with the U.S. Food and Drug Administration. If successful, this would entitle Eton to 180 days of generic exclusivity. Cysteine hydrochloride injection is an old molecule that was sold in the United States for decades as an unapproved product before Exela's New Drug Application approval in 2019. Exela did not conduct any new clinical studies to support its NDA filing, and instead relied on historic published literature to support its safety and efficacy claims. Eton's own development partner had manufactured and commercialized cysteine hydrochloride injection over fifteen years ago in the same formulation that was claimed to be novel by Exela Pharma Sciences, and as a result, Eton is highly confident that the Exela Pharma Science patents will be invalidated. In addition, Eton expects to file Post Grant Reviews with the U.S Patent and Trademark Office later this month. The PGR process is an abbreviated pathway to challenge the validity of patents issued by the USPTO. The USPTO is generally required to make a final ruling on a PGR challenge within eighteen months of a challenger's PGR submission, which would allow for Eton to potentially launch its product as early as November 2021.

09:08 EDT Overwatch League, Call of Duty League announce collaboration with Sportradar - The Overwatch League and Call of Duty League, two global, city-based esports organizations, and Sportradar announced an agreement for a comprehensive integrity program to protect both leagues from betting-related corruption. Under the terms of the deal, Sportradar will monitor global betting activity related to domestic and international Overwatch League and Call of Duty League competitions organized by Activision Blizzard Esports and will report any potential integrity issues to the company to help safeguard the integrity of the competitions. Sportradar will also provide both leagues with access, as needed, to its specialized Intelligence and Investigation Services unit. Further, Sportradar will help educate players on betting integrity risks and rules and will also develop an app to enable players to anonymously report suspected integrity issues. The company's Integrity Services support more than 80 of the most prominent US and international sports and esports bodies, including the NFL, NBA, MLB, NHL, FIFA and Tennis Australia.

09:07 EDT H2O Innovation eases salary reductions - H2O Innovation provided a new update following its March 31 press release in response to the current situation surrounding COVID-19. Given the Corporation's good financial health, the management has decided to ease its extraordinary salary reduction measures. In addition, the Corporation is preparing to resume its manufacturing activities for its Maple and Projects business lines, due to upcoming deliveries and the reopening of various construction sites. Considering H2O Innovation's financial situation over the last few weeks, the Corporation has decided to review certain extraordinary measures implemented since March 30. On May 4, the 10% reduction in the wages of some of its employees went to a 5% reduction. "Since we did not observe any significant deterioration in the Corporation's financial situation, management decided to ease the wage reduction measures, that had been implemented as a preventive measure at the beginning of the pandemic", stated Frederic Dugre, President and Chief Executive Officer of H2O Innovation. However, the 15% reduction for its officers and its Board of Directors remains until further notice. The internal COVID-19 intervention team continues to meet three times a week. The team is currently working, in collaboration with the managers of the different business lines, on a gradual return-to-work protocol for telework employees, while respecting the prevention and safety measures put in place by the various governments. A specific protocol for each office, each manufacturing plant and each site will be developed and shared with employees next week. "Being considered as an essential service provider, H2O Innovation has been able to maintain its operations and maintenance activities, after-sales services, manufacturing and distribution of specialty chemicals, and design and manufacturing of components for desalination and maple farming equipment. Only the Projects business line was slowed down due to limited access to various construction sites. Since we have the indication that several regions are gradually reopening, now is the time to prepare for the gradual return-to-work of our telework employees. While ensuring the continuity of our operations, safety remains our priority, and that is why we will continue to adapt our work environments, encourage physical distancing and promote best hygiene practices", added Frederic Dugre, President and Chief Executive Officer of H2O Innovation.

09:06 EDT Eros Now announces partnership with Visa - Eros Now, the digital over-the-top, or OTT, South Asian entertainment platform owned by Eros International (EROS) announced its partnership with Visa (V). This collaboration allows Visa Debit and Credit Card users in India to avail of Eros Now's massive content library including 12,000 plus movie titles, original shows, music videos, short format content - Quickies, at a discount to the annual Eros Now subscription price. This partnership will offer Visa cardholders a discount of 50% on their annual subscription to Eros Now and access to a plethora of entertainment from cult Bollywood movies such as Maine Pyaar Kiya, Rangeela, Hum Dil De Chuke Sanaam to Love Aaj Kal, Tanu Weds Manu, Manmarziyaan, amongst others. The library also entails originals from the house of Eros Now that caters to varied genres such as drama, thriller, comedy, to name a few.

09:05 EDT Tecogen receives order for Tecochill CH-50 from Florida gas utility - Tecogen announced an order for a Tecochill CH-50 air-cooled chiller from a municipal gas utility in Florida. The system is replacing an existing Tecochill chiller that has reached its end of useful life. The system will provide cooling for the company's headquarters as well as free hot water for domestic purposes and will be serviced out of Tecogen's Florida factory service center. Florida has some of the lowest gas rates in the country, and gas utilities are looking at additional ways to expand gas consumption in the state. The state recently approved natural gas as an emergency fuel for assisted living facilities, whereas traditional electric chillers require the purchase of an equivalently sized diesel-powered standby generator to continue operating the chillers in a power outage. Many Florida utilities also offer discounted gas delivery tariffs to customers using Tecogen equipment, as well as energy efficiency incentives. Customers who are able to purposefully use the free recovered engine waste heat can also qualify for the 10% investment tax credit offered by the federal government for combined heat and power systems.

09:04 EDT Grifols' Proceix Panther System approved by FDA - Grifols has received FDA approval for the Procleix Panther System featuring ART for use with the following U.S. licensed products: Procleix Ultrio Elite Assay, Procleix WNV Assay, Procleix Zika Virus Assay and the Procleix Babesia Assay. ART supports laboratory efforts to reach complete sample automation. The Procleix Panther System featuring ART has been available since October 2019 in all markets accepting the CE-mark.

09:02 EDT Rubius Therapeutics doses first patient in Phase 1/2 trial of RTX-240 - Rubius Therapeutics announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors. RTX-240 is an allogeneic, off-the-shelf Red Cell Therapeutic that is engineered to mimic the human immune system by stimulating adaptive and innate immunity to generate an anti-tumor immune response. RTX-240 is engineered to express a co-stimulatory molecule, 4-1BB ligand, and a cytokine, IL-15TP, on the cell's surface and is designed to broadly stimulate the immune system by activating and expanding both natural killer cells and T cells to generate a potent anti-tumor response.

09:02 EDT TransUnion, Horizon Media partner to build data identity backbone - To create better experiences for both brands and consumers, Horizon Media has partnered with TransUnion to expand its identity capabilities. The partnership will empower more personalized marketing execution in support of people-based marketing and client advertising initiatives. The partnership uses TransUnion's validated identity and robust audience attribute data sets to help build Horizon's identity spine from the ground up, creating a common ID layer to power marketing decisions across all touchpoints. Through the partnership, Horizon bolsters its own identity infrastructure, establishing a framework for reconciling disparate data sources, deepening its client's data-driven strategies, and enabling faster connections to deliver IDs across the digital ecosystem.

09:01 EDT Global Blood Therapeutics announces new employment inducement grants - Global Blood Therapeutics announced that on May 1, 2020, the compensation committee of GBT's board of directors granted seven new employees restricted stock units for an aggregate of 36,500 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The 2017 Inducement Equity Plan was adopted by GBT's board of directors in January 2017 and has been amended and restated from time to time.

09:01 EDT Enlivex Therapeutics initiates multi-center Phase II clinical trial of Allocetra - Enlivex Therapeutics announced that an investigator-initiated multi-center Phase II clinical trial of Allocetra in COVID-19 patients has commenced. The COVID-19 study is a multi-center investigator-initiated, Phase II clinical trial. The trial is expected to recruit up to five patients in each participating center and is designed to assess Allocetra in combination with standard of care therapy in patients with COVID-19 associated lung dysfunction. Safety, tolerability, cytokine profile and efficacy parameters will be evaluated, with change in PaO2/FiO2 ratio number and severity of adverse events and serious adverse events serving as the co-primary study endpoints. The COVID-19 study is expected to run independently of Enlivex's currently planned Phase IIb clinical trial of Allocetra for the treatment of sepsis. The planned Phase IIb trial will be a controlled, randomized study that is expected to commence in the fourth quarter of 2020.

08:58 EDT Tetraphase reports unsolicited takeover proposal from La Jolla Pharmaceutical - In a regulatory filing, Tetraphase Pharmaceuticals (TTPH) disclosed that it received an unsolicited proposal from La Jolla Pharmaceutical Company (LJPC) to acquire Tetraphase for $22M in cash, plus an additional $12.5M in cash potentially payable under contingent value rights to be issued in the transaction. Tetraphase previously announced that it had entered into a merger agreement, dated as of March 15, with AcelRx Pharmaceuticals (ACRX). "Tetraphase is evaluating the La Jolla proposal and has not made a determination as to whether it constitutes a superior proposal under the terms of the AcelRx merger agreement," the filing noted.

08:56 EDT CB2 Insights achieves target of reaching profitability - CB2 Insights has announced that it has achieved its target of reaching profitability. On an unaudited basis, the Company has seen positive EBITDA for April 2020. Amidst the ever-evolving COVID-19 pandemic, the Company continues to work hard to prioritize achieving full profitability. This will allow the Company to strengthen its cash balance and remove all reliance on external capital for activities beyond strategic initiatives. The Company will use only cash derived from operations to support current and new projects. Further, the Company has seen a growth of 25% in patient visits during the month of April compared to the same period in the prior year. Total patient visits in April 2020 were 6,756 for the month compared to 5,366 in April 2019. The Company continues to see accelerated growth in patient volume driven through national brand exposure, competitive marketing and patient acquisition strategies as well as effective patient retention programs. Additionally, the Company expects to see further growth as a result of recent laws in the US allowing for telemedicine to be utilized for medical cannabis certifications across all the states the Company operates in. This will provide the Company the ability to access remote parts of each state where services are either limited or unavailable to patients. With a team of over 70 healthcare providers, the Company has the scale and size to support patients across the state and is focusing on expanding its marketing efforts to support this expansion. The Company also recently announced the launch of Skylight Health Group as part of its clinical operations in the United States. SHG, which will provide a range of integrated health services such as primary medical care, consultative specialist care and alternative health, wellness & multi-disciplinary services will operate under an insurable integrated model in accordance with the rules, regulations and requirements by the Centers for Medicare and Medicaid Services. Provision of insurable services to patients at a limited or no cost will allow greater access for patients who are currently unable to afford such care as a result of growing unemployment rates due to the Covid-19 pandemic. Both initiatives in addition to other projects the Company is currently working on will be funded solely through profits generated from operations.

08:53 EDT ViacomCBS accelerating plans for expanded streaming service

08:52 EDT Plug Power announces progress in Hydrogen Vertical Integration strategy - Plug Power is pursuing transactions to acquire United Hydrogen Group Inc. and an electrolyzer technology platform company. Both acquisitions are in line with Plug Power's overall green hydrogen business strategy to have over 50% of hydrogen be green by 2024 and, if successfully completed, are expected to enhance Plug Power's capabilities in hydrogen generation, liquefaction and logistics business. Plug Power is in advanced negotiations to acquire United Hydrogen. Plug Power owns a convertible bond in United Hydrogen, which could represent over 30% equity ownership on a converted basis. United Hydrogen is the first independent company that brings a full suite of experience in production, distribution and logistics of liquid hydrogen, similar to industrial gas companies. If completed, the acquisition is expected to be accretive immediately and to have a meaningful positive impact on Plug Power's cost of hydrogen, especially as the Company goes into 2021 and beyond. Today, United Hydrogen produces 6.4 tons of hydrogen daily with plans to increase to 10 tons daily in the near future, and with goals of further expansion. This 6.4 tons of daily liquid hydrogen generation capacity has a low carbon footprint as it uses by-product hydrogen from chlor alkali plants. Plug Power's hydrogen vertical integration strategy is designed to make hydrogen fuel ubiquitous while controlling fuel cost and turning this into a cash flow generating business. In line with this green hydrogen strategy, Plug Power is also pursuing the acquisition of an electrolyzer company. If the acquisition is completed, this technology platform is expected to provide Plug Power access to a range of electrolyzer products from 100kW to 1MW+. In addition, Plug Power's manufacturing scale and experience is expected to allow for rapid scaleup of this product line. Plug Power has a growing pipeline of opportunities with its customers where the value proposition works well with electrolyzer technology today. In addition, this technology is expected to allow for Plug Power to expand its addressable market opportunity into other industrial applications. Leveraging electrolyzer and low-cost renewable power is key to a green hydrogen economy and is in line with our stated goal of having over 50% of hydrogen to be green by 2024. According to Bloomberg New Energy Finance, the cost of green hydrogen is expected to decline by over 50% by 2030. Plug Power has not yet entered into a definitive acquisition agreement with either acquisition target and both transactions are subject to the completion and execution of customary definitive documents and satisfaction of customary closing conditions. While Plug Power cannot guarantee that either acquisition will be completed, based on the current state of negotiations and transaction process, the company expects both acquisitions can be completed by the end of the second quarter of 2020.

08:51 EDT Alio Gold, Argonaut Gold merger receives positive reccomendation from proxy firm - Argonaut Gold and Alio Gold are pleased to announce that Glass, Lewis & Co. has issued positive reviews of the proposed merger announced on March 30, 2020. Leading proxy advisory firms, Glass Lewis and Institutional Shareholder Services Inc. both recommend that Argonaut and Alio shareholders vote in favour of the resolutions to be voted on at the special meetings of shareholders to be held on May 20, 2020. Argonaut and Alio shareholders of record at the close of business on March 30, 2020 and April 14, 2020 respectively are eligible to vote their common shares. Full details of the proposed merger and the matters to be voted on at the meeting are described in the joint management information circular and related meeting materials that were mailed to shareholders on April 22, 2020. All of the meeting materials can be downloaded from Argonaut's website at http://www.argonautgold.com/ and from Alio's website at http://www.aliogold.com/ and also from each company's profile on SEDAR at www.sedar.com. To proactively deal with the unprecedented public health impact of COVID-19, both meetings will be held in a virtual only format.

08:48 EDT Medipharm Labs Australia granted GMP certificate, license - MediPharm Labs announced that its subsidiary, MediPharm Labs Australia has been granted its GMP Certification and Licence to Manufacture Therapeutic Goods, a key milestone in the advancement of the Company's global supply chain strategy and a catalyst for revenue generation in Australia. The Licence was granted by the Australian Therapeutic Goods Administration - the branch of the Australian Government's Department of Health responsible for regulating therapeutic goods including prescription medicines, vaccines and medical devices. The TGA is one of 53 regulatory authority members of the Pharmaceutical Inspection Co-operation Scheme, an international co-operative arrangement among regulatory authorities in the field of Good Manufacturing Practice for medicinal products. The PIC/S mission is to lead the development, implementation and maintenance of harmonised GMP standards and quality systems of inspectorates in the field of medicinal products. Many PIC/S members, such as the TGA, also enter into mutual recognition agreements with other PIC/S members whereby each regulatory authority specifically recognizes certain processes and procedures of the other country to expedite the international flow of goods. The Licence confirms that MediPharm Labs Australia complies with the internationally recognized GMP requirements of the PIC/S Guide for Medicinal Products and allows the manufacture of therapeutic goods intended for export or which are exempt from registration and listing on the Australian Register of Therapeutic Goods under the provisions of Section 18(1) or Section 19 (1)(a) of the Therapeutic Goods Act. Under the Licence, MediPharm Labs Australia may store cannabis resin as an Active Pharmaceutical Ingredient ("API") and may engage in packaging, storage and release for supply as a Medicine Manufacturer of Oral Liquids within its specialized facility in Wonthaggi, Victoria. In 2020, MediPharm Labs Australia has secured several medicinal cannabis supply agreements for both Australia and New Zealand reflecting the growing commercial opportunity in these markets. With this licence in place, it expects to ramp up supply of GMP-compliant products and begin fulfilment of new and upcoming supply agreements upon receiving final product approvals. Construction of the MediPharm Labs Australia facility began in 2018 and was completed in December 2019. Also in December 2019, MediPharm Labs Australia received State Licences for cannabis substances from the Department of Health and Human Services in Victoria, Australia. Under these State Licences, MediPharm Labs Australia is allowed to manufacture, store, and supply cannabis products and medicines and, for research purposes, test cannabis at its facility. MediPharm Labs Australia also has its Cannabis Manufacturing Licence from the Australian Office of Drug Control under the Narcotic Drugs Act 1967. MediPharm Labs Australia holds ODC Import and Export Licences, allowing import and export of cannabis resin and extracts, bulk medicinal cannabis oil and finished medicinal cannabis products. MediPharm Labs Australia was designed to replicate the high-quality standards of the Company's Canadian production facility. It features multi-phase supercritical CO2 extraction equipment, softgel capsule manufacturing equipment, clean rooms and testing laboratories and has TGA manufacturing approval for labelling and packaging lines.

08:47 EDT First Bancshares announces renewal of share repurchase plan - First Bancshares announced the renewal of its share repurchase program that previously expired on December 31, 2019. Under the program, the company may, but is not required to, from time to time repurchase up to $15M of shares of its common stock in any manner determined appropriate by the company's management.

08:46 EDT CACI awarded $63M task order to upgrade U.S. Army infrastructure in INDOPACOM - CACI International announced that it has been awarded a five-year task order, with a ceiling value of $63M, to upgrade U.S. Army infrastructure across the U.S. Indo-Pacific Command, or INDOPACOM, including by providing continued enterprise support for the relocation of the Army's garrison at Yongsan, Seoul, South Korea to Camp Humphreys. CACI engineers and technicians will provide enterprise expertise and technology to the Army's Program Executive Office Enterprise Information Systems through the task order, awarded under the NETCENTS-2 contract vehicle, including by engineering, furnishing, installing, securing, and testing upgraded infrastructure at 46 Army sites throughout the theater. CACI is also modernizing the command, control, communications, computers, and intelligence network infrastructure of those Army sites under a separate contract, allowing the company to provide end-to-end expertise to the Army as the military service completes its upgrades. The new work performed under the contract will complement network infrastructure upgrades made for the Army by CACI in INDOPACOM, such as those under the Yongsan Relocation Plan. CACI experts have assisted the Army in planning, designing, engineering, installing, and testing the communications network infrastructure throughout South Korea to support its consolidation at Camp Humphreys and across the INDOPACOM theater.

08:45 EDT Mesa Air reports 10,297 block hours in April - Mesa Air Group reported Mesa Airlines' operating performance for April 2020. Mesa Airlines reported 10,297 block hours in April 2020, a 72.4 percent drop from April 2019 as a result of reduced schedules during the COVID-19 outbreak. The company also reported a controllable completion factor of 100 percent for both its American and United operations. Commenting on the results, Mesa Air Group Chairman and CEO Jonathan Ornstein said, "In my more than 20 years as CEO I have never seen a sustained drop in demand like this. It's an incredibly difficult time for everyone, but I am extremely proud of our people for running a perfect operation during a challenging month."

08:41 EDT Teva says 'very sustainable' generic business, including biosimilars

08:40 EDT Puma licensing partner CANbridge receive marketing approval for NERLYNX in China - Puma Biotechnology announced that its licensing partner CANbridge Pharmaceuticals has received marketing approval of NERLYNX in mainland China from the National Medical Products Administration, or NMPA, of China. NERLYNX is indicated for the extended adjuvant treatment of adult patients with early stage human epidermal growth factor receptor 2, or HER2, positive breast cancer, to follow adjuvant trastuzumab-based therapy.

08:39 EDT ViacomCBS: Pluto TV's domestic MAU's grew to 24M+, up 55% y/y

08:38 EDT JetBlue sees Q2 capacity down about 80% vs. original plan - JetBlue said earlier: "Although the overall number of bookings remained extremely limited, we believe that we reached the bottom in terms of demand around mid-April, and expect to have a better sense of third and the fourth quarter of 2020 by early summer."

08:37 EDT JetBlue: March capacity declined 19% y/y

08:36 EDT Aeglea BioTherapeutics announces program highlights - Pegzilarginase in Arginase 1 Deficiency: Aeglea is working with treating physicians to implement individual treatment plans and potentially developing a home healthcare option for patients enrolled in the Phase 3 PEACE trial. To date, most enrolled patients have continued to receive treatment. The Company is developing a plan to analyze results for patients that are missing data points. The Phase 3 PEACE trial protocol is designed in such a way that a patient may miss a few doses without being disqualified from the trial. The supply chain has not experienced any significant impact at this time and the Company currently has sufficient supply available for completion of its ongoing clinical trials. The Company expects to complete enrollment of its Phase 3 PEACE trial in the third quarter of 2020 and to provide topline data in the first quarter of 2021. ACN00177 in Homocystinuria: In April, Aeglea announced the approval of its Clinical Trial Application by the United Kingdom's Medicines and Healthcare Products Regulatory Agency for ACN00177, a novel engineered human enzyme therapy designed to treat Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine which leads to a wide range of life-altering complications and reduced life expectancy. The Company continues its patient identification and administrative activities to quickly move forward with dosing patients once trial sites are able to initiate clinical trials. While Aeglea continues to prepare to initiate a Phase 1/2 trial for ACN00177 in the second quarter of 2020, the timing will depend on determination by individual sites that each is ready to open for recruitment in light of COVID-19; the Company's priorities at this time are to avoid further overburdening hospital staff and to minimize the risk of trial participants exposure to COVID-19.

08:35 EDT Aeglea BioTherapeutics expects capital to fund operations through 2022 - As of March 31, 2020, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $50.5 million. In addition, in April 2020 the Company raised approximately $129.6 million in net proceeds from a public offering. Based on Aeglea's current operating plan, and taking into account the net offering proceeds, management believes it has sufficient capital resources to fund anticipated operations through 2022.

08:30 EDT Ryman Hospitality reaffirms withdrawl of FY20 guidance

08:28 EDT Williams announces agreement on Deepwater Gulf project with Chevron - Williams (WMB) announced that it has reached an agreement with Chevron (CVX) and its co-owner, Total E&P USA, to provide offshore natural gas transportation services to the Anchor development. Anchor is located 140 miles off the coast of Louisiana in the Green Canyon area of the Gulf of Mexico. "Chevron plans to drill multiple wells and construct a floating production platform capable of handling the new rich natural gas and oil production from the Anchor development. Williams will leverage its existing footprint and system capabilities to transport Anchor's natural gas production to the Discovery system, of which Williams is 60% owner and operator; DCP is 40% owner. The new rich natural gas will be transported to Discovery's processing plant in Larose, Louisiana, and the natural gas liquids will be fractionated and marketed at Discovery's Paradis plant in Louisiana." Anchor is expected to come online in the first half of 2024.

08:25 EDT Daseke initiates plan to strategically divest Aveda assets, operations - During the first quarter of 2020, management initiated a plan to strategically divest Aveda's assets and operations. The portion of Aveda's assets and operations that management plans to sell have been classified as held for sale as of March 31, 2020. Chief Executive Officer Chris Easter concluded, "We have spent several months studying the Aveda business relative to our operational footprint and strategic focus, and have taken several actions to better align its cost structure and performance. Our management and board of directors have concluded that the Aveda business is not a long-term fit with the rest of our portfolio, and as a result, we have elected to begin the process to strategically divest this business. Following its conclusion, our Oil and Gas related business should represent less than two percent of our go-forward revenues."

08:24 EDT Endo reports Q1 International Pharmaceuticals segment revenue $29M - Q1 International Pharmaceuticals segment revenues of $29 million were comparable to the same period in the prior year.

08:24 EDT Endo reports Q1 Generic Pharmaceuticals revenue $251M vs. $219M last year - Q1 Generic Pharmaceuticals segment revenues were $251 million, an increase of 15% compared to $219 million in first-quarter 2019. This increase was primarily attributable to recent product launches and accelerated prescription fulfillment resulting from consumer access concerns related to the COVID-19 pandemic and was partially offset by continued competitive pressure on commoditized generic products. During first-quarter 2020, the Generic Pharmaceuticals segment launched four products.

08:22 EDT Endo reports Q1 Sterile Injectables segment revenue $336M vs. $270M last year - Q1 Sterile Injectables segment revenues were $336 million, an increase of 25% compared to $270 million in first-quarter 2019. This increase reflects the strong growth of VASOSTRICT and ADRENALIN resulting primarily from significantly increased sales volume towards the end of the quarter due to higher utilization primarily to treat patients infected with COVID-19, increased channel inventory stocking and price.

08:20 EDT Soligenix receives $840K in funding through New Jersey tax transfer program - Soligenix has received approximately $840K, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program. This competitive program enables approved technology and biotechnology businesses to sell their unused Net Operating Loss Carryovers and unused Research and Development Tax Credits to unaffiliated, profitable corporate taxpayers in the state of New Jersey. This allows businesses with NOLs to turn their tax losses and credits into cash proceeds to fund additional R&D, purchase equipment and/or facilities, or cover other allowable expenditures.

08:19 EDT Ideanomics' MEG enters agreement with China's BXGI for EV financing - Ideanomics' MEG division announced an agreement with Beijing Xinneng Green Intelligent Network to help finance the replacement of its urban fleet with electric vehicles in China over the next five years, starting in 2020. The Group's fleet operations consist of more than 100,000 city buses. Upon conversion to EVs, it is estimated that this fleet will require a significant charging port infrastructure to accommodate the energy demand to power its EV fleet operations. The value of replacing the BXGI fleet will reach the equivalent of several billion dollars in local currency over the five-year period. To finance this purchase, BXGI has secured between $113M and $140M. Working with its consortium of financial partners, MEG will assist BXGI with securing the balance of the financing. The fund is expected to close in Q3 and proceeds will be used to purchase electric buses.

08:16 EDT Calyxt sees collaborations providing cash milestone payments in near-term - "The COVID-19 pandemic has caused an unprecedented global crisis. I am very proud of the dedication and resilience of the Calyxt team and of the actions we have taken in response to the COVID-19 pandemic to protect our employees and our business," said Jim Blome, Calyxt CEO. "Most of our laboratory workers remain onsite at our headquarters and all workers who are able to work remotely have done so since early in the crisis. Protecting our scientists and their projects is critical to our future, and thus far we have handled the transition without disruption. I appreciate the actions of our team to help ensure we stay safe and on track. While the immediate future is uncertain, what is crystal clear is that Calyxt must act judiciously and decisively to succeed during this situation and after it is resolved. We have taken several measures to respond to a dynamic environment that compels us to bolster our liquidity and rapidly adapt to extraordinary circumstances. The first quarter of 2020 was initially marked by increasing demand for our high oleic soybean products, offset in the latter part of the quarter by the beginning of the COVID-19 pandemic, which has temporarily disrupted the agricultural and food supply chains globally and depressed food industry demand for premium oil. These negative effects increased throughout the quarter and remain with us today. We have responded to ongoing disruptions by pausing our crush schedule to preserve cash, while continuing our seed distribution activities for 2020 plantings, and continuing to ship high oleic soybean oil to our recently announced world-class oil customer. Looking forward at the macro-environment, we expect prices for both oil and meal to remain low, demand for oil to remain depressed and, depending on livestock herd sizes, meal demand may also be depressed. We also expect some of the oil and meal price pressure to be partially offset by lower grain purchase costs. Despite these headwinds, we continue to geographically expand our soybean meal customer base and continue to sample and test with large consumer packaged goods companies. I am confident that when the macro-environment stabilizes, we will emerge stronger than before. On the technology front, we continue to build out and improve our gene editing technology suite. We licensed a new breakthrough from the University of Minnesota, invented in a lab run by Calyxt co-founder Dan Voytas, Ph.D., that will enable us to significantly reduce the time needed to develop traits in certain crops. I am pleased with the four product candidate advancements in our development process in the quarter, especially considering the unique nature of each. Our innovative technology, continuous improvement and robust scientific team are what allows us to maintain a competitive edge in the gene editing space," continued Blome. "In the near-term, we expect to launch our first hemp product - improved plants to address key problems facing hemp growers - marking the launch of our second commercial product. We expect the velocity of our revenue opportunities to accelerate as we build up a robust portfolio of commercial products addressing several different markets. For our efforts to secure new collaboration agreements with industry partners, we aim to sign multiple new agreements this year. We expect collaboration agreements to provide us with cash milestone payments to further support our liquidity and our vision that Calyxt is an innovation platform company. In summary, despite increased headwinds and unprecedented global disruption, we continue to execute on our business initiatives, improve our gene editing platform, drive forward our R&D programs, and extend our cash runway. I am incredibly proud of our team and look forward to sharing more on our developing story at the upcoming BMO Global Farm to Market Virtual Conference on May 13," concluded Blome.

08:14 EDT Teva seeing 'slow improvement' in revenue, earnings - Says past the trough.

08:13 EDT Shell Midstream plans to maintain quarterly distribution of 46c per common unit - Because of the continuing impacts of the global COVID-19 pandemic and lack of clarity on crude and finished products supply and demand in the near-term, the Partnership is updating prior guidance for the remainder of 2020. The Partnership currently intends to maintain a distribution of $0.46 per common unit for the second quarter of 2020 and plans to access its credit facilities if needed to make up for any operational cash shortfalls. The Partnership's Board of Directors will monitor the business environment and make decisions regarding future distributions on a quarter by quarter basis. The Partnership anticipates its coverage ratio for the second quarter of 2020 to be less than 1.0x, but given the current level of uncertainty, it is unable to provide further guidance at this time. SHLX continues to monitor the volatile business environment and will provide further updates on its Q2 2020 conference call with analysts and investors. The Partnership's available liquidity as of March 31, 2020 was approximately $1.2 billion, and SHLX does not expect to have any near-term need to access the capital markets for debt or equity. Additionally, SHLX has no scheduled near-term maturities of its senior notes or credit facilities, with the earliest scheduled maturity in 2022.

08:10 EDT Teva says no impact on ongoing clinical trials from COVID-19

08:09 EDT Arcadia Biosciences awarded four new patents - Arcadia Biosciences announced the U.S. Patent and Trademark Office has awarded the company two patents for extending the shelf life of whole wheat by minimizing hydrolytic and oxidative rancidity. The company also received notices of allowance for two additional patents extending earlier claims surrounding the extended shelf life of wheat and reduced gluten grains. The new patents bring the total number of patents in Arcadia's GoodWheat portfolio of non-genetically modified wheat varieties to 22.

08:07 EDT Agree Realty raises quarterly dividend 2.6% to 60c per share - The dividend is payable July 10 to shareholders of record at the close of business on June 26.

08:06 EDT Teva says all facilities remain open to meet demand for medicines - Says has adequate inventory, raw materials to meet demand. Comments taken from Q1 earnings conference call.

08:02 EDT Selecta Biosciences announces upcoming milestones - Topline Results from COMPARE Clinical Trial Expected in the Third Quarter of 2020: The head-to-head COMPARE study of Selecta's lead product candidate, SEL-212, vs. pegloticase is expected to readout on schedule, as the Company continues to work closely with the CRO and clinical sites to monitor patient follow-up in light of the COVID-19 pandemic. The trial is evaluating a once-monthly dose of SEL-212 compared to biweekly doses of pegloticase, with the primary endpoint of the maintenance of serum uric acid levels of less than6mg/dL at three and six months. The trial completed enrollment in December 2019, and as of April 2020, half of the patients had completed the study and all patients had reached three months of treatment. Gene Therapy Program Expected to Enter the Clinic by the End of 2020: Selecta and its partner AskBio are jointly developing a broad portfolio of next-generation AAV gene therapies. This partnership will leverage the unique proprietary technology platforms of both companies with a human proof of concept trial to validate this portfolio of products and their potential for re-dosing in patients, which could represent a significant advancement in the gene therapy field. Selecta and AskBio anticipate entering the clinic by the end of 2020. Additionally, Selecta intends to advance its proprietary program in Ornithine Transcarbamylase deficiency.

08:00 EDT Albireo Pharma expects cash balance to be sufficient into 2H21 - The company had cash and cash equivalents at March 31, 2020, of $150.5 million, which compares with $150.3 million at March 31, 2019. During the first quarter of 2020, an additional $43.0 million of net cash was raised through an underwritten public offering of our common stock. As a result, cash and cash equivalents are anticipated to be sufficient into the second half of 2021.

07:56 EDT Huntington Ingalls sees 2020 shipbuilding sales growth at low end of 3%-5% - "Given the unprecedented visibility and stability provided by our $45 billion in backlog, and our strong balance sheet, we remain confident in our ability to minimize the impact of COVID-19 on our business and to achieve the long-term financial targets we provided in February," said Chris Kastner, HII chief financial officer. "However, due to reduced attendance in the shipyards, we see shipbuilding sales growth for the year to be at the lower end of the previously provided range of 3 to 5 percent."

07:55 EDT Rite Aid 'significantly' expands COVID-19 testing - Rite Aid will significantly expand its COVID-19 testing effort with the addition of 46 no-charge testing sites, most of which will operate through its stores' drive-through windows, beginning May 11, 2020. Rite Aid is also expanding COVID-19 testing criteria at all testing sites to include adults who are not exhibiting any symptoms of the virus, effective immediately in accordance with the Centers for Disease Control and Prevention guidance. All Rite Aid COVID-19 testing locations utilize self-swab nasal tests overseen by Rite Aid pharmacists. At all testing locations, patients are required to provide government issued identification, be at least 18 years old, and need to pre-register online at www.riteaid.com in order to schedule a time slot for testing. Rite Aid will now operate 71 testing sites across twelve states through its partnership with the U.S. Department of Health and Human Services. Rite Aid's self-testing parking lot sites are open from 9 a.m. - 5 p.m. seven days a week. Rite Aid testing locations operating through its stores' drive-through windows are open Monday through Friday 10 a.m. - 8 p.m. and Saturday and Sunday 10 a.m. - 5 p.m. Rite Aid has the capacity to conduct up to 10,000 tests daily across all locations through online appointments. Rite Aid has partnered with Verily and will use its Baseline COVID-19 Program to provide screening, scheduling and return of results to participants for Rite Aid testing sites. Rite Aid also selected BioReference Laboratories to provide COVID-19 laboratory testing to all drive-up locations with the goal of flattening the curve through accessible diagnostic testing. Clinical oversight for the COVID-19 testing program is provided by PWNHealth, a national clinician network that enables safe and easy access to diagnostic testing. Rite Aid will continue to provide regular updates on the company's progress with COVID-19 testing.

07:52 EDT Verrica Pharmaceuticals expects cash to support operations at least through 2Q21 - As of March 31, 2020, Verrica had aggregate cash, cash equivalents, and marketable securities of $88.4 million, which the Company believes will be sufficient to support planned operations, including expenses for the potential commercialization of the Company's lead product candidate, VP-102, as well as the ongoing development of the compound for additional indications, including common warts and external genital warts, and the development of VP-103 for plantar warts, at least through the second quarter of 2021.

07:50 EDT Orchard Therapeutics expects cash, investments to fund operations into 2022

07:48 EDT Middleby sees new restaurant openings severely impacted for remainder of year - "Our restaurant customers have been significantly impacted due to restrictions on foodservice establishments and shelter at home orders," commented Mr. FitzGerald. "Accordingly, in our Commercial Foodservice segment we have seen an approximate 65% decline of incoming orders in April compared to 2019 orders. While the continuing impact remains unpredictable, the restaurant industry has reported sales improvements every week during the month of April, from the sharp decline beginning in mid-March. We anticipate new restaurant openings will be severely impacted for the remainder of the year, but historically most of our sales in this segment are equipment replacement and upgrades in conjunction with new menu initiatives or operational improvements. During this crisis, our foodservice customers have focused on their delivery, drive-through and carry-out business. We are able to support these customers with innovative products and technology solutions to address workplace safety, evolving business needs and continued operating essentials. Our strategic investments over the past year have well-positioned us for current industry trends, which we expect to accelerate as our foodservice customers adopt a new work environment. At our Residential Kitchen businesses, in both the U.S. and UK markets, the impact of COVID-19 included significant closures of our residential dealers' retail sales locations and substantial decline in traffic resulting from shelter at home orders. The decline in incoming order rates for the month of April amounted to approximately 53%. Although demand will continue to be adversely impacted and uncertain, we may see a positive benefit as dealer retail locations will begin to re-open in May. The Food Processing Group, entered the year with a record backlog of approximately $138 million, which continued to outpace revenue growth and grew to approximately $152 million to end the first quarter. This existing backlog provides stability within this business segment for the upcoming quarters. The impact of COVID-19 was reflected in April incoming orders, which declined by approximately 28% as our customers focused on immediate issues and risks to their business and employees. End-user demand for our food processing customers has shifted from restaurants to retail grocery stores, impacting sales mix, although overall industry demand continues to be relatively stable. Sales of certain food items, such as hot dogs and other meat products in our core equipment markets, have experienced recent increased demand. While the disruption caused by COVID-19 may continue to impact near-term purchasing decisions, we are well-positioned to support the demand for large scale equipment solutions in this industry. Operators continue to look for improvements in food and employee safety, labor and finished product costs, as well as addressing capacity expansion and production efficiencies." Mr. FitzGerald concluded, "We have taken swift and aggressive measures to adjust to near-term market conditions, which we anticipate will improve as we progress through the balance of the year. During this time our focus remains on the safety of our employees, the supporting of our customers and maintaining profitability margins and cash flow. We are confident in our ability to navigate through this period of uncertainty. We will continue to leverage our industry-leading capabilities within our broad portfolio of brands, supplying product innovation to a diversified customer base. This will continue to enhance our strong financial position moving forward."

07:46 EDT Moderna up 14% after FDA clears Phase 2 COVID vaccine study to proceed - Moderna, along with its report earlier of financial results for the first quarter of 2020, announced that the U.S. Food and Drug Administration completed its review of the company's Investigational New Drug, or IND, application for its novel coronavirus - SARS-CoV-2 or COVID-19 - vaccine candidate, mRNA-1273, allowing it to proceed to Phase 2 study, expected to begin shortly. The company also noted it is finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020. In pre-market trading, Moderna shares are up $6.78, or 13.9%, to $55.73.

07:43 EDT Autolus Therapeutics announces key upcoming milestones - Dosing of first patient in the pivotal program, AUTO1-AL1 in adult ALL in Q2 2020. Additional clinical data at upcoming conferences: Annual Meeting of the American Society of Clinical Oncology: Update on the AUTO3 ALEXANDER study in DLBCL patients. Annual Meeting of the European Hematology Association: Update on AUTO1 ALLCAR19 study in adult ALL patients. Additional preclinical data at the American Association for Cancer Research II meeting across multiple programs; AUTO5 in T-cell lymphomas, AUTO6NG and AUTO7 in solid tumors. Ph2 decision for AUTO3 in DLBCL mid-2020. Initiation of an outpatient cohort in the AUTO3 ALEXANDER study in H2 2020. Further updates for both AUTO1 and AUTO3 in Q4 2020. Interim Ph1 data for AUTO4 in T cell lymphoma in Q4 2020. Progression of additional next generation programs from preclinical stages to Ph1 through H2 2020 into H1 2021. Expansion of the company's suite of cell programming technologies to include additional modules designed for allogeneic applications, with the first novel allogeneic program expected to enter the clinic in Q4 2020.

07:42 EDT Equinox Gold announces PEA for Aurizona Gold Mine in Brazil - Equinox Gold is pleased to announce a positive preliminary economic assessment for development of an underground mine at the company's 100% owned Aurizona Gold Mine in Brazil. The underground mine could be operated concurrently with the existing open-pit mine and has the potential to deliver an additional 740,500 ounces of gold, $1B in revenue and $204M in after-tax net cash flow over a ten-year mine life at a base case gold price of $1,350 per oz.

07:39 EDT Momenta sees 2020 non-GAAP operating expenses $220M-$240M - Non-GAAP operating expense is total operating expenses, less stock-based compensation expense, restructuring expense and collaborative reimbursement revenues. Due to lower clinical trial enrollment trends as a result of the COVID-19 pandemic, Momenta anticipates its full-year non-GAAP operating expenses will be lower than $220 - $240 million, as previously guided for 2020. The Company anticipates providing an update on expected non-GAAP operating expense for 2020 as part of its second quarter 2020 financial results.

07:37 EDT Editas Medicine announces programs outlook - In Vivo CRISPR Medicines: EDIT-101 for LCA10: First in vivo CRISPR medicine administered to a patient; Editas Medicine and Allergan announced the treatment of the first patient in the BRILLIANCE Phase 1/2 clinical trial of EDIT-101 at Oregon Health & Science University Casey Eye Institute, a world-recognized academic eye center. The study has been cleared to continue based on a review of safety data on the first patient. The Company plans to complete dosing of the adult low-dose cohort and to dose at least one patient of the adult mid-dose cohort by the end of 2020. EDIT-102 for Usher Syndrome 2: Ready for IND-enabling studies pending Allergan option exercise; Under the terms of its 2017 alliance agreement with Allergan, Editas Medicine has delivered a preclinical data package to Allergan for potential licensing. EDIT-102 is ready for IND-enabling studies pending Allergan's option exercise. A decision is expected by the third quarter of 2020. Autosomal Dominant Retinitis Pigmentosa 4: Nomination of development candidate delayed to 2021. Due to interruptions from the COVID-19 outbreak, Editas Medicine is delaying to 2021 the declaration of a development candidate for an experimental medicine to treat autosomal dominant retinitis pigmentosa 4. Engineered Cell Medicines: EDIT-301 for Sickle Cell Disease and Beta-Thalassemia: IND filing expected by end of 2020. Editas Medicine is developing EDIT-301 using Cas12a (Cpf1), a proprietary enzyme, as a potentially best-in-class medicine to treat sickle cell disease and beta-thalassemia. Preclinical in vivo toxicology studies are in progress and the Company expects to file an IND for sickle cell disease by the end of 2020. EDIT-201 to Treat Solid Tumors: Declared candidate and initiated IND-enabling studies for allogeneic NK cell medicine: EDIT-201 is an allogeneic healthy-donor natural killer (NK) cell medicine for the treatment of solid tumors. Editas Medicine plans to present preclinical data on EDIT-201 at a scientific conference in the second half of 2020.

07:35 EDT Editas Medicine expects cash to fund operating expenses for next 24 months - The Company expects that its existing cash, cash equivalents and marketable securities of $415.0 million at March 31, 2020, and anticipated interest income will enable it to fund its operating expenses and capital expenditures for at least the next 24 months. The Company remains committed to diligently managing expenses to maintain a strong balance sheet moving forward.

07:32 EDT Flir Systems awarded additional $20.6M Army contract for Black Hornet 3 PRS - Flir Systems announced it has won an additional $20.6M contract from the U.S. Army to deliver its Flir Black Hornet 3 personal reconnaissance systems, or PRS. The advanced nano-unmanned aerial vehicles, or UAVs, will support platoon- and small unit-level surveillance and reconnaissance capabilities as part of the Army's soldier borne sensor, or SBS, program. In January 2019, the U.S. Army awarded FLIR an initial $39.7M contract for Black Hornet 3's to support the SBS program. The company is currently delivering those systems for fielding across the force.

07:30 EDT Penn National down 2.6% after reporting Q1 results

07:29 EDT Penn National says long-term growth strategy remains 'on course' - Penn National CEO Jay Snowden said, "During the mandated closures of our properties, our management team has undertaken a comprehensive reevaluation of our corporate and property operating structures to improve efficiencies, and we are exploring new technologies and innovations that could help reimagine our casinos and enhance the guest experience. We are also in the process of making meaningful upgrades to expand the reach of our industry-leading mychoice loyalty program. We expect the mychoice program to be a powerful tool for our omni-channel strategy, and we are taking steps to connect our land-based casinos to our sports betting and iCasino products to offer customers a compelling incentive to consolidate play across our various platforms. This omni-channel approach will be bolstered by the broad appeal of Barstool Sports, and we look forward to attracting Barstool fans to our casinos through special events and talent appearances once the virus has subsided. While our operating team has been busy reconfiguring our casinos for a post-COVID-19 world, our interactive team has been hard at work laying the foundation for future growth online. We have been able to continue the development of our Barstool Sportsbook app and remain on schedule for launch in the third quarter of 2020 on what we anticipate will be a more level playing field with our competitors given the extended absence of major live sports in the months leading up to our launch. Our team of engineers is creating a best-in-class sports betting product, and the Barstool brand, loyal audience and marketing engine will help drive meaningful market share as the product is introduced across our database of 20 million casino customers and Barstool's audience of over 66 million fans. The past several weeks have also reinforced our investment thesis in Barstool Sports. Despite the lack of live sporting events, Barstool has continued to create highly entertaining content in recent weeks, with blog traffic increasing over 20% in April, video views up over 50% and social media accounts seeing meaningful growth. In addition, Barstool has shown continued success in utilizing emerging platforms to expand its reach, including explosive growth on TikTok and the introduction of live video game streaming on Twitch. Barstool's highly diverse and engaging content is proving to be more relevant than ever in the key demographics we will be targeting, and we continue to believe Barstool's growing, loyal audience will lead to meaningful reductions in customer acquisition and promotional costs for our sports betting product. While Penn National's overall first quarter results were mixed due to the coronavirus, Penn Interactive had a notably strong first quarter, beating budgeted revenue and EBITDA despite the loss of retail sportsbook revenue for most of March. That momentum has carried into the second quarter, with Penn Interactive experiencing significant growth in users and revenue for both its social and real money gaming products. We are especially encouraged by the early results of our iCasino product in Pennsylvania. Despite the state's excessively high tax rate, which has limited our marketing spend, 40,000 customers have registered for our iCasino product thus far, with roughly 66% of those players being new to our ecosystem or reconnected former patrons. The average age of these players is much younger than our core land-based player, which highlights the lack of cannibalization iCasino has had on our brick and mortar business in the first quarter. Our experience in Pennsylvania has reinforced our view that our casino operating prowess and database will be a significant competitive advantage as additional states authorize iCasino over the coming years - particularly when combined with the potential for significant iCasino cross-sell from the Barstool Sportsbook. Penn National is the only operator in the U.S. with a large, geographically diversified land-based gaming footprint, a well-known sports brand, a fully aligned marketing partner and a wholly-owned sports betting and iCasino subsidiary. As such, we are strongly positioned to benefit from the continuing proliferation of sports betting and iCasino legislation - something we expect to accelerate as states seek new tax revenues in the aftermath of the virus. While the last several weeks have been challenging for the Company, our team members and the entire industry, we remain firmly convinced of the long-term potential of our highly differentiated omni-channel approach."

07:28 EDT Amicus announces 2020 key strategic priorities - Achieve $250 million to $260 million of global product revenue for Galafold; Complete Pompe Phase 3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA; Advance clinical development, manufacturing and regulatory discussions for CLN6 and CLN3 Batten programs; Progress Pompe gene therapy towards Investigational New Drug application and disclose up to two additional IND candidates; Maintain strong financial position.

07:26 EDT The Buckle reports April sales down 80.8% to $11.4M - The Buckle reported total net sales for the 4-week fiscal month ended May 2 decreased 80.8% to $11.4M from net sales of $59.6M for the prior year 4-week fiscal month. Net sales for the 13-week fiscal quarter ended May 2, 2020 decreased 42.7% to $115.4M from $201.3M for the prior year 13-week fiscal quarter ended May 4, 2019. Online sales for the quarter increased 31.5% to $32.1M for the 13-week period ended May 2, vs. $24.4M for the 13-week period ended May 4, 2019. Buckle closed all brick and mortar stores due to the COVID-19 pandemic for an indefinite period beginning March 18. The company began the process of reopening certain stores the week of April 26, following state and local reopening guidelines. As of May 2, 37 stores had reopened, with approximately 100 additional stores reopening the week of May 3. The company's online store has remained open without interruption. The company does not plan to separately report comparable store sales during this time.

07:25 EDT Aldeyra announces new clinical program in systemic inflammatory diseases - Aldeyra plans to assess the activity of ADX-629 in three types of severe inflammation: cytokine release syndrome, autoimmune disease, and allergy. In preclinical models, ADX-629 treatment reduced levels of TH1, TH2, and TH17-related cytokines, suggesting potential activity across a broad array of inflammatory diseases. The timing of clinical trial initiation depends, in part, on restrictions related to COVID-19, the availability of clinical research facilities and staffing, and the ability to recruit patients. COVID-19 Respiratory Compromise: A Phase 2 clinical trial of ADX-629 is expected in subjects with COVID-19-associated respiratory compromise, defined as hypoxia and pulmonary radiographic involvement, immediately following admission to the hospital. Severe inflammation, characterized in part by cytokine release syndrome, leads to acute respiratory distress syndrome and other conditions that require mechanical ventilation. The clinical trial, contingent on FDA review of information submitted via the Coronavirus Treatment Acceleration Program, or CTAP,, is expected to begin in the third quarter of 2020. Autoimmune Disease: A Phase 2a clinical trial of ADX-629 in patients with psoriasis, an autoimmune condition associated with TH1 cytokines, is expected to begin in the second half of 2020. Allergy: A Phase 2a allergen-challenge clinical trial of ADX-629 in patients with atopic asthma, an allergic inflammatory disease associated with TH2 cytokines, is expected to begin in the second half of 2020.

07:23 EDT Laureate Education implements actions to reduce cash outlays, expenses - The company said, "For the past five years, Laureate has invested in building capacity to deliver high-quality, digital learning experiences for its students. From fully online universities, such as Walden University, to campus-based universities offering a combination of campus-based and online learning environments, Laureate students around the world are familiar with this mode of delivery, and faculty understand the importance of harnessing the power of technology to create authentic, personal, and innovative learning experiences for students. Prior to the COVID-19 pandemic, 28% of the teaching hours across Laureate's campus-based institutions were already being taught online as we deliver our educational offerings in a hybrid delivery model emphasizing both face-to-face and online learning. This compares to just 3% in 2014 when Laureate first started to invest in the digital enablement of its campus-based institutions. This expertise allowed all of Laureate's institutions to quickly transition to fully online in a matter of weeks and resulted in minimal disruptions to students as they were able to continue their educational programs in a high-quality online learning environment. Laureate students are now taking classes in an innovative learning environment enabled by a common learning management system (LMS) platform operated across most of the Company's network universities. Our investments in digital instruction, coupled with an ongoing commitment to quality and online learning, allow Laureate to complement synchronous, real-time instruction with the benefits of high-quality, engaging student instruction delivered through asynchronous means. We are committed to serving students with innovative and effective learning tools during this crisis and beyond. Given the uncertainty that exists as to the extent and duration of the COVID-19 pandemic, Laureate has proactively implemented a number of actions to reduce cash outlays and expenses, including freezing of non-essential capital expenditures until visibility improves and a reduction of more than $100 million in operating expenses, which includes temporary reductions in compensation for its CEO, executive management and board members. If the recovery takes longer than expected, Laureate expects to take additional actions. As previously announced, Laureate's Board of Directors has authorized the Company to explore strategic alternatives for each of its business units, evaluating all potential options, including sales, spin-offs or business combinations. The rationale for embarking on the strategic review process has not changed. However, as a result of the COVID-19 pandemic and its continuing effect on market conditions, the strategic review is progressing at a slower pace than anticipated. There can be no assurance as to how long the exploration of strategic alternatives will take, that these processes will result in the completion of any transaction, or as to the values that may be realized from any potential transaction. Laureate does not intend to provide further interim updates on the progress of this review unless and until it believes disclosure is appropriate."

07:21 EDT ViacomCBS, Google expand distribution agreement, financial terms not disclosed - ViacomCBS (VIACA, VIAC) and Google (GOOG, GOOGL) announced a comprehensive, multi-year distribution agreement to deliver more content from ViacomCBS' leading portfolio of news, entertainment and sports networks for YouTube TV subscribers. In addition to featuring continued carriage of CBS broadcast stations, CBS Sports Network, Pop TV, Smithsonian Channel, and The CW, the expanded agreement introduces 14 ViacomCBS channels to the live TV and on-demand subscription service. BET, CMT, Comedy Central, MTV, Nickelodeon, Paramount Network, TV Land and VH1 will launch on YouTube TV this summer, providing more than two million subscribers with access to some of the most popular cable brands. BET Her, MTV2, Nick Jr., NickToons, TeenNick and MTV Classic will also launch on YouTube TV at a later date. The deal also includes a continued commitment to distribute ViacomCBS' premium subscription services, including SHOWTIME, on YouTube TV, as well as an extended partnership on the broader YouTube platforms. Financial terms of the agreement were not disclosed.

07:17 EDT Plug Power reaffirms guidance to achieve $300M in gross billings in 2020 - Plug Power reaffirms guidance to achieve $300M in gross billings in 2020, which represents more than 25% growth year over year. This pandemic is causing a global economic slowdown, affecting business and families around the world. No one is immune from the magnitude of this economic downturn. We at Plug Power are also impacted by this, but given our mix of customers and product offerings, we remain on track to deliver on our stated objective of gross billings guidance for full-year 2020. More specifically, we are seeing increasing demand from our customers focused on delivery of mission critical products and online sales which should offset the anticipated slowdown for our manufacturing customers, particularly automotive customers. In addition, recurring revenue from long term contracts, which annually can be expected to represent at least 30% of sales, also provides a buffer to our full year forecast in these times of economic uncertainties.

07:16 EDT Plug Power remains 'on track' to deliver 2024 targets - The company said, "We remain focused on building the hydrogen economy. We have already initiated key steps towards vertical integration of hydrogen generation business while continuing to work with new and existing strategic partners. Our 2024 targets remain $1B in gross billings, $170M in operating income, and $200M in adjusted EBITDA."

07:14 EDT Apple awards $10M to Copan Diagnostics to accelerate COVID-19 testing - Apple announced it is awarding $10M from its Advanced Manufacturing Fund to Copan Diagnostics, which specializes in sample collection kits that play a critical role in COVID-19 testing. This funding will allow Copan Diagnostics to rapidly accelerate their supply of sample collection kits for hospitals across the United States, expanding production from several thousand to more than 1M kits per week by early July. As part of this effort, Apple will support Copan Diagnostics' expansion to a new, larger facility in Southern California, with advanced equipment that Apple is helping design. This expansion is expected to create more than 50 new jobs. Apple is sourcing equipment and materials for Copan Diagnostics from companies across the U.S., including equipment Apple is helping design from K2 Kinetics, based in York, Pennsylvania, and MWES in Waukesha, Wisconsin.

07:12 EDT Athenex announces upcoming milestones - An abstract for the ongoing Phase 2 study of Oral Paclitaxel in angiosarcoma has been accepted for presentation in a poster discussion session at the American Society of Clinical Oncology's upcoming ASCO20 Virtual Scientific Program, which will be held from May 29 to May 31, 2020. FDA acceptance of the NDA for Oral Paclitaxel for metastatic breast cancer. PDUFA date of December 30, 2020 for tirbanibulin ointment for actinic keratosis.

07:11 EDT Aaron's recorded goodwill impairment charge of $446.9M in Q1 - The company concluded that the need for an interim goodwill impairment test was triggered for the Aaron's Business segment as of March 31, 2020, primarily as a result of a significant decline in the Company's stock price and market capitalization in March 2020 as well as other factors. With the assistance of a third-party valuation firm, we determined that the Aaron's Business goodwill was fully impaired, and, as a result, recorded a non-cash goodwill impairment charge of $446.9M during the three months ended March 31, 2020. This assessment entailed estimating the Aaron's Business reporting unit's fair value and comparing this estimate to the carrying value. The estimated fair value was derived using a combination of income and market approaches.

07:11 EDT Armstrong Flooring reports preliminary April sales down 20% globally - Nearly all state and local governments in the U.S. have classified construction as an essential business. However, inconsistent state and local government orders have resulted in varying impacts to the Company's results across geographies and for some customers. While home centers continue to operate, independent customer retail locations are closed in some cases. Although some commercial projects in the retail sector have been postponed, most education and healthcare projects are moving forward. These factors, together with the social distancing and shelter-in-place guidelines by local authorities, have resulted in a softer demand environment since the second half of March 2020. During the month of March 2020, net sales declined 15% year-over-year, primarily driven by lower North American volume into the end of the period. Preliminary April net sales were down approximately 20% globally compared to April 2019.

07:06 EDT Carrols Restaurant provides business update amid COVID-19 outbreak - The company said, "Since the onset of the COVID-19 pandemic, we have taken numerous steps to adapt our business to the current environment as well as to better position the Company for the future. These steps include: Continuing to serve drive-thru and, at certain locations, at the counter for take-out as we prioritize the health and safety of our employees and customers. Take-out and drive-thru orders comprised approximately 75% of restaurant sales in 2019; Keeping our restaurants stocked with hand sanitizers, masks, gloves, and thermometers; Launching delivery services to the majority of our Burger King and Popeyes restaurants, ahead of our original timetable. Delivery sales are now approximately $800,000 per week (approximately 3% of total restaurant sales); Modifying restaurant operating hours based on day-part sales trends and local ordinances while making adjustments to have the appropriate amount of labor for all operating day parts; Rationalizing all ongoing expenses, and where possible, reducing corporate and regional overhead and restaurant labor, cost of sales, and operating expense levels. These adjustments include reducing regional and corporate overhead by $5 million to $7 million on an annualized basis, achieved by streamlining our regional management structure, a 10% reduction in non-restaurant wages, instituting a company-wide hiring freeze, and adjusting restaurant labor costs to reflect revised restaurant hours and accessibility; Working closely with our landlords to negotiate reduced or deferred cash rent obligations and optimizing payment terms with key vendors and suppliers; Revaluating all capital expenditures and delaying all projects that have not yet commenced other than critical restaurant maintenance issues. Approximately $25 million of capital expenditure spending was incurred during the first quarter, the majority of which was carryover spend from projects commenced in 2019. Full year estimated range of capital expenditure spending is $35 million to $40 million, net of sale lease-back proceeds; Suspending any acquisition activity and our stock repurchase program; Temporarily closing 46 locations in March, 2020, including 42 Burger King and four Popeyes restaurants that were geographically close to other Company restaurants; Opening five Burger King restaurants to date in 2020 that commenced construction in 2019 and closing 11 restaurants year-to-date that were EBITDA negative; and Enhancing our sources of liquidity by increasing our revolver borrowing capacity by $30.8 million to a total of $145.8 million on April 8, 2020. As of May 5, 2020, we had $111.8 million of outstanding borrowings and $9.7 million of letters of credit issued under our revolving credit facility. In terms of liquidity, as of May 5, 2020 the Company had $77.8 million of available funds consisting of $24.4 million available to be drawn on the Company's revolving credit facility and approximately $53.4 million in cash deposits."

07:03 EDT GasLog Partners, GasLog CFO Alastair Maxwell to step down - GasLog Ltd. (GLOG) and GasLog Partners LP (GLOP) announced that, following GasLog's decision to base its senior management, including the CFO position, in Greece, Alastair Maxwell has decided not to relocate and will therefore step down from his position as CFO on June 30, 2020. The Boards of GasLog and GasLog Partners have appointed Achilleas Tasioulas, who is presently Deputy CFO, as CFO, effective July 1, 2020. During this period, Alastair will work closely with Achilleas to ensure an orderly transition of responsibilities and Alastair will remain available after leaving to provide his experience and advice, if required.

07:00 EDT Quanta Services announces actions in response to COVID-19 pandemic - The company said, "Quanta has taken proactive measures to protect the health and safety of its employees. In February, the company implemented its pandemic plan, which includes a focus on prevention, preparedness and response. We have operated based on the guidelines set forth by the Centers for Disease Control and Prevention and the Occupational Safety and Health Administration and are monitoring conditions on a real-time basis. We have also implemented initiatives in response to the pandemic such as specialized training, social distancing, additional protective equipment for our employees in the field, and additional sanitizing measures for offices, vehicles and equipment. We have canceled non-essential business travel, applied work from home policies where appropriate and developed other human resource related guidance to help employees stay safe and healthy. As of March 31, 2020, Quanta had approximately 39,500 employees and to date has not experienced any meaningful health impact on availability of our workforce or key personnel as a result of the COVID-19 pandemic. Additionally, Quanta implemented its business continuity plan and has been collaborating with customers to minimize potential service disruptions and to proactively anticipate how COVID-19 may impact the company's operations. Further, Quanta's pandemic plan has been made available to our customers and vendors as an additional resource. Although there are no immediate threats to resources needed to continue serving customers, Quanta is in constant communication with its workforce, suppliers and partners and continues to monitor developments that may affect our operations. In the latter part of the first quarter and continuing into the second quarter, shelter-in-place restrictions in some of our service areas created disruptions to portions of our operations. Even though our services are critical infrastructure and deemed essential, certain major metropolitan markets that have been meaningfully impacted by COVID-19 such as Detroit, New York and Seattle shut down work. The pandemic has also compounded challenges that the broader energy market is experiencing, which is affecting portions of our Pipeline and Industrial Infrastructure Services segment. Quanta is also experiencing some minor permitting delays due to the COVID-19 pandemic, but is not experiencing and does not expect to experience significant supply chain disruptions or workforce availability issues. As a result of these dynamics, we expect our second quarter results to be meaningfully impacted, and have reduced our expectations for the second half of the year. However, state and local governments are beginning to ease restrictions, and we are planning with our customers for the disruptions to our work to moderate. The ultimate impact of the COVID-19 pandemic on Quanta's operational and financial performance will depend on future developments, including the duration and severity of the pandemic and actions taken by domestic and international governments in response to the pandemic, all of which are uncertain and cannot be predicted. We continue to actively monitor the current environment for risks related to the pandemic in order to prepare and respond accordingly."

06:57 EDT Raytheon Technologies not providing an outlook due to COVID-19 pandemic - The company said: "The financial impact of the COVID-19 pandemic cannot be reasonably estimated at this time. The extent of such impact depends on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge. Given the ongoing uncertainty regarding the scope, severity and duration of the COVID-19 pandemic, RTC is not providing an outlook at this time and will revisit providing a 2020 outlook at our next earnings release."

06:54 EDT Kontoor Brands announces temporary suspension of dividend

06:54 EDT Independence Contract Drilling reports 17 rigs earning revenues in Q1 - Independence Contract Drilling exited Q1 with 17 rigs earning revenues under drilling contracts and expects to exit Q2 with 6 rigs earning revenues under drilling contracts. The company's backlog of drilling contracts with original terms of 6 months or longer was $26.4 million as of March 31, representing 3.58 rig years of activity. All of this backlog is expected to be realized during the remainder of 2020.

06:43 EDT HollyFrontier sees lower demand continuing into Q2 - The company said, "The COVID-19 pandemic caused a decline in U.S. and global economic activities during the first quarter of 2020. As a result, the demand for, and the resulting price we receive for, the sale of our products, including gasoline, jet fuel, lubricants and other products, has decreased during the last weeks of the first quarter of 2020. We expect the lower product prices and lower demand to continue into the second quarter of 2020."

06:39 EDT KAR Auction provides update on impact of COVID-19 on operations - KAR Auction said, "The company has altered its processes to comply with all local, state and provincial directives, including social distancing guidelines, which have materially limited ADESA's ability to provide its full scope of services until the guidelines are eased or terminated. As a result, the company has taken certain measures to help protect the business and its liquidity while its operations are negatively impacted. Some of these measures include the following: The company has reduced compensation expense: The company's CEO, CFO and President have voluntarily elected to forgo 100% of their respective base salaries effective April 5, 2020 through at least June 27, 2020. The remainder of the company's executive officers have voluntarily elected to reduce their base salaries by 50% during this period. Base salaries across many levels of the organization have been temporarily reduced. The company furloughed approximately 11,000 employees in April 2020. The company's board of directors voluntarily elected to forgo their cash compensation for the second quarter of 2020. Business travel for any reason has been prohibited. Non-essential services provided by third parties at the company's locations have generally been suspended. All capital projects at the company's physical auction locations have been delayed or canceled. The company has temporarily suspended its quarterly dividend in light of the impact of the COVID-19 pandemic on its operations. The company has negotiated the deferral of rent payments with certain landlords. The ADESA Assurance program was temporarily suspended. AFC has reduced the unused portion of certain floorplan lines with its customers.In addition, the company intends to take advantage of the Employee Retention Credit and the Federal Employer Social Security Tax Deferment provided under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). Recent restrictions on retail automobile sales and operations have reduced floorings and payoffs at AFC. As a result, AFC launched a Customer Relief Program in March 2020. Under the Customer Relief Program, eligible customers may choose to defer curtailment payments (principal, fees and interest) due through May 31, 2020, on eligible units. The extent to which the COVID-19 outbreak impacts the company's business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, the company may continue to experience materially adverse impacts to its business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future."

06:35 EDT Lexington Realty provides April rent update - As of May 6, 99.8% of April cash base rents have been paid. Lexington has received rent relief requests from certain tenants. The amount of rent relief requests Lexington has received represented 5.5% of its 2019 annual Cash Base rents. Lexington estimates the portion of tenants warranting relief represented less than 1% of its 2019 annual Cash Base Rents. Lexington is currently evaluating these requests, but, absent material tenant defaults, Lexington does not expect any material impact to its rental revenues resulting from rent relief requests.

06:33 EDT EQT Corporation reports Q1 sales volumes of 385 Bcfe - EQT Corporation reports Q1 sales volumes of 385 Bcfe or 4.2 Bcfe per day, 20 Bcfe above midpoint of first quarter guidance.

06:32 EDT AmerisourceBergen announces new $500M share repurchase plan - In May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the company to purchase up to $500M of its outstanding shares of common stock, subject to market conditions. As of March 31, the company had $68.8M remaining under the share repurchase program authorized in October 2018.

06:31 EDT 36Kr Holdings announces up to 1M share repurchase program - 36Kr Holdings announced that the board of directors of the company approved a share repurchase program, under which 36Kr is authorized to repurchase up to a total of 1M of its ADSs, each representing 25 Class A ordinary ahares. The share repurchase plan will be effective after the release of the company's operating and financial results for Q1 on Form 6-K, which is to be filed with the SEC on or before June 30, subject to the relevant rules under the Securities Exchange Act of 1934, as amended and the company's insider trading policy. Also, 36Kr announced that its executive officers, Dagang Feng, Jihong Liang and Yang Li, and certain other employees of the company have undertaken in writing that upon the expiry of the lock-up period, for an additional 180 days, they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any ordinary shares, ADSs or securities convertible into or exchangeable or exercisable for any ordinary shares or ADSs.

06:30 EDT AB InBev sees impact of COVID-19 'materally worse' in Q2 vs. Q1 - The company said: "We expect that the impact on our 2Q20 results will be materially worse than in 1Q20. This has already become evident in our April 2020 global volumes, which declined by approximately 32%, primarily driven by the closure of the on-premise channel in most markets and government restrictions imposed on certain operations of ours in connection with the COVID-19 pandemic."

06:25 EDT Far Point Acquisition recommends stockholders vote against Global Blue deal - Far Point Acquisition announced that, after careful consideration and consultation with its management and outside legal advisors, its board has unanimously determined that the previously announced business combination transaction with Global Blue is not advisable or fair to, or in the best interest of, FPAC and its stockholders. Also, the board unanimously recommends that FPAC's stockholders vote against the transaction when a vote occurs. The company said, "FPAC will continue to work with Global Blue under the terms of FPAC's agreement with Global Blue and other parties (the "Merger Agreement") to finalize the proxy statement (the "Proxy Statement") and will call a special meeting of FPAC's stockholders to vote on the Transaction as promptly as practicable. When filed, the Proxy Statement will elaborate on the reasons why the Board unanimously recommends that stockholders vote against the Transaction. The Board determined unanimously that failure to change its recommendation would reasonably be expected to constitute a breach of its fiduciary obligations to FPAC stockholders. In addition, FPAC is withdrawing all previously announced guidance regarding the Transaction, its timing and, based on information received from Global Blue's management, the forecasted results of Global Blue.The Board's decision to change its recommendation is based on a number of factors, including that: (1) Global Blue management has informed FPAC that the ongoing COVID-19 pandemic is having a significant negative impact on Global Blue's financial condition, revenues and results of operations; and (2) FPAC management informed the Board that it no longer supports the Transaction and believes, based on its assessment of information received from Global Blue, that there is a likelihood that Global Blue will lack sufficient capital and liquidity to fund its operations and satisfy its financial obligations following the closing of the Transaction. FPAC's management also informed the Board of its view that the current value of the Transaction to FPAC is far less than the value contemplated when the Board approved the Transaction. If the Transaction is approved by FPAC stockholders, there remains a risk that one or more conditions to the closing, including whether Global Blue has suffered a material adverse effect and whether it can meet New York Stock Exchange listing requirements, will not be satisfied. FPAC reserves its rights to assert that those or other conditions to closing cannot be satisfied, as well as all other rights under the Merger Agreement. Accordingly, there is no certainty the Transaction will close prior to August 31, 2020, the date on which any party may terminate the Merger Agreement subject to its terms. "

06:22 EDT Ball reports Q1 Beverage Packaging, S. America sales $405M vs. $441M last year - Beverage packaging, South America, comparable segment operating earnings for the first quarter 2020, were $63 million on sales of $405 million compared to $68 million on sales of $441 million during the same period in 2019. Segment demand was up 1 percent in the quarter with solid demand in Chile, Argentina and Paraguay offset by meaningfully slower market conditions in Brazil during the second half of March. Foreign exchange headwinds and customer mix also impacted year-over-year results. "As we look forward, performance in the second quarter is expected to be significantly lower in Brazil due to regional government decisions to close small grocery stores and gas stations during the initial impact of the pandemic in April and lower overall consumer spending for beverages. Segment operations will continue to monitor trends and closely align production with customer demand in the near-term, and focus on operational and cost efficiencies until an anticipated market rebound in late 2020. As such, the two Brazilian production lines slated to come on line in the fourth quarter will likely shift into 2021 and, when appropriate, existing plants in Brazil will support surrounding countries given stronger demand in those regions."

06:21 EDT Ball Corp. reports Q1 Beverage Packaging, EMEA sales $669M vs. $684M last year - Beverage packaging, EMEA, comparable segment operating earnings for the first quarter 2020 were $68 million on sales of $669 million compared to $74 million on sales of $684 million during the same period in 2019. Beginning this quarter, current and historical quarterly results for the company's existing facilities in Cairo, Egypt, and Manisa, Turkey, have been consolidated into the segment. 5% segment volume growth was unable to fully offset euro earnings translation headwinds, higher freight and warehousing costs due to sales demand shifts by region and intermittent production line downtime late in the quarter. Demand was driven by packaging mix shift to cans for traditional and non-traditional beverages, strong growth for energy drinks and higher at-home consumption in the U.K., Europe and Russia offset lower demand in Turkey. Projects for multiple beverage can line additions will be executed across the existing European plant network in 2020 and beyond to meet demand recovery, however, certain work has been delayed to the second half due to country-specific travel restrictions and employee safety considerations associated with our project engineering team. Demand and business conditions are expected to be challenging in the second quarter and the company currently expects earnings in this segment to be down mid-single digits as overall consumption - particularly in the immediate consumption channels - remains subdued, while results for the second half are expected to reflect notable year-over-year improvement as new capacity ramps up, and the expectation that consumer demand improves.

06:13 EDT Dish reports Q1 net Pay-TV subscribers down by about 413K - Net Pay-TV subscribers decreased by approximately 413,000 in the first quarter, compared to a net decrease of 259,000 in the year-ago quarter. Net Pay-TV subscriber additions/losses and Pay-TV churn rate for the period ending March 31 were not adjusted for the impact of the COVID-19 pandemic.

06:11 EDT Iron Mountain provides business, cost containment update amid COVID-19 - Meaney continued, "Whilst we are fortunate that Iron Mountain is considered an essential service in many locations and sectors where we operate, we have seen a slowdown in our service business driven by the numerous country and local shutdowns, and the substantial increase in remote working policies across organizations. As such, we have taken a number of steps to help Iron Mountain withstand the crisis, reduce operating expenses and create financial flexibility." Iron Mountain has also taken actions to maintain financial and strategic flexibility, including: Terminating nearly all temporary and contract workers; Introducing furloughs, mandatory vacation or sick time off, and other temporary compensation reduction measures for approximately one-third of its global workforce to align with near-term activity levels; Deferring certain previously planned non-essential capital investments and implementing a temporary freeze in M&A spend. Meaney concluded, "Decisions that impact our employees are never taken lightly and we have set up numerous resources to support impacted employees during this unprecedented time. As we look ahead, we are focused on managing the health of the business to ensure we can continue providing a premier experience to our customers. I am especially proud of all of our teams that have come together to address the unique challenges presented by the pandemic."

06:08 EDT CommScope sees Q2 sales, adjusted EBITDA 'improving modestly' vs. Q1 - "Given the dynamic nature and unprecedented situation, we are taking decisive actions to strengthen our financial position and prudently manage our balance sheet. These actions include adjusting our operating plan to reduce costs and capital expenditures and drawing $250 million on our ABL revolving credit facility as a precautionary measure to preserve financial flexibility," said Alex Pease, Executive Vice President and Chief Financial Officer. "While our business to date has proven to be remarkably resilient and we have seen extremely strong order rates across certain critical segments, we are acutely aware of the strains on the global economy and the impact that could have on many of our customers, particularly in the enterprise space. Due to this ongoing market uncertainty created by the COVID-19 pandemic, we are not providing specific guidance for the second quarter of 2020 and we are withdrawing our full year outlook. However, we do expect our second quarter sales and non-GAAP adjusted EBITDA to improve modestly compared to the first quarter."

06:05 EDT Hilton reports Q1 system-wide comparable RevPAR decreased 22.6% - On a currency neutral basis.

05:26 EDT Leju changes independent registered public accounting firm - Leju Holdings announced that the company has appointed Yu Certified Public Accountant as its independent registered public accounting firm for the fiscal year ended December 31, 2019. At the same time, the company and Deloitte Touche Tohmatsu Certified Public Accountants have mutually agreed to terminate Deloitte's appointment as the company's independent registered public accounting firm. The change of the company's independent registered public accounting firm was approved by the Audit Committee of its board, and was not the result of any disagreements between the company and Deloitte on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.